<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-id journal-id-type="iso-abbrev">Cardiovasc Diabetol</journal-id><journal-title-group><journal-title>Cardiovascular Diabetology</journal-title></journal-title-group><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28599667</article-id><article-id pub-id-type="pmc">5466779</article-id><article-id pub-id-type="publisher-id">554</article-id><article-id pub-id-type="doi">10.1186/s12933-017-0554-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sardu</surname><given-names>Celestino</given-names></name><address><phone>++390815665110</phone><email>drsarducele@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Barbieri</surname><given-names>Michelangela</given-names></name><address><email>michelangela.barbieri@unicampania.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Santamaria</surname><given-names>Matteo</given-names></name><address><email>matteo.santamaria@fgps.it</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Giordano</surname><given-names>Valerio</given-names></name><address><email>valerio.giordano@me.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sacra</surname><given-names>Cosimo</given-names></name><address><email>cosimo.sacra@fgps.it</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Paolisso</surname><given-names>Pasquale</given-names></name><address><email>pasquale.paolisso@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Spirito</surname><given-names>Alessandro</given-names></name><address><email>alessandro.spirito@insel.ch</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Marfella</surname><given-names>Raffaele</given-names></name><address><email>raffaele.marfella@unicampania.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Paolisso</surname><given-names>Giuseppe</given-names></name><address><email>Giuseppe.paolisso@unicampania.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rizzo</surname><given-names>Maria Rosaria</given-names></name><address><email>mariarosaria.rizzo@unicampania.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania &#x0201c;Luigi Vanvitelli&#x0201d;, Piazza Miraglia, 2, 80138 Naples, Italy </aff><aff id="Aff2"><label>2</label>Cardiovascular and Arrhythmias Department, John Paul II Research and Care Foundation, Campobasso, Italy </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0479 0855</institution-id><institution-id institution-id-type="GRID">grid.411656.1</institution-id><institution>Cardiovascular Department, </institution><institution>Inselspital of Bern University, </institution></institution-wrap>Bern, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>6</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>16</volume><elocation-id>75</elocation-id><history><date date-type="received"><day>12</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Type 2 diabetes mellitus (T2DM) is a multi factorial disease, affecting clinical outcomes in failing heart patients treated by cardiac resynchronization therapy with a defibrillator (CRT-d).</p></sec><sec><title>Methods</title><p>One hundred and ninety-five T2DM patients received a CRT-d treatment. Randomly the study population received a CRT-d via multipolar left ventricle (LV) lead pacing (n 99, multipolar group), vs a CRT-d via bipolar LV pacing (n 96, bipolar group). These patients were followed by clinical, and instrumental assessment, and telemetric device control at follow up. In this study we evaluated, in a population of failing heart T2DM patients, cardiac deaths, all cause deaths, arrhythmic events, CRT-d responders rate, hospitalizations for HF worsening, phrenic nerve stimulation (PNS), and LV catheter dislodgment events (and re-intervention for LV catheter re-positioning), comparing multipolar CRT-d vs bipolar CRT-d group of patients at follow up.</p></sec><sec><title>Results</title><p>At follow up there was a statistical significant difference about atrial arrhythmic events [7 (7%) vs 16 (16.7%), p value 0.019], hospitalizations for HF worsening [15 (15.2% vs 24 (25%), p value 0.046], LV catheter dislodgments [1 (1%) vs 9 (9.4%), p value 0018], PNS [5 (5%) vs 18 (18.7%), p value 0.007], and LV re-positioning [1 (1%) vs 9 (9.4%), p value 0.018], comparing multipolar CRT-d vs bipolar CRT-d group of patients. Multipolar pacing was an independent predictor of all these events.</p></sec><sec><title>Conclusions</title><p>CRT-d pacing via multipolar LV lead vs bipolar LV lead may reduce arrhythmic burden, hospitalization rate, PNS, LV catheters dislodgments, and re-interventions in T2DM failing heart patients.</p><p>
<italic>Clinical trial number</italic> NCT03095196</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Type 2 diabetes mellitus (T2DM) is a worldwide increasing disease [<xref ref-type="bibr" rid="CR1">1</xref>]. T2DM may impact on heart functions [<xref ref-type="bibr" rid="CR2">2</xref>], leading to cardiovascular disease [<xref ref-type="bibr" rid="CR3">3</xref>]. An evident correlation exists between T2DM, and heart failure (HF) disease [<xref ref-type="bibr" rid="CR4">4</xref>]. In fact, T2DM may condition HF disease progression, its clinical stage, and the response to therapeutic treatments [<xref ref-type="bibr" rid="CR4">4</xref>]. In HF patients, cardiac resynchronization therapy with a defibrillator
(CRT-d) is a well-established treatment to improve symptoms, quality of life, New York Heart Association (NYHA) class, and clinical outcomes [<xref ref-type="bibr" rid="CR5">5</xref>]. On other hand, the T2DM clinical stage, the glucose homeostasis, the insulin therapy, and the ageing may affect CRT-d response, and the related clinical outcomes [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. In last decades, the advancement of CRT-d technology worked to reduce implant complications, as phrenic nerve stimulation (PNS), and left ventricle (LV) leads dislodgments [<xref ref-type="bibr" rid="CR13">13</xref>], and to improve clinical outcomes in CRT-d patients [<xref ref-type="bibr" rid="CR14">14</xref>]. In this setting, CRT-d pacing via a multipolar LV lead may represent one of these technological advancements. In fact, the stable and continuous CRT-d pacing by multipolar LV lead looked to condition the clinical prognosis, and CRT-d responders rate in failing heart patients [<xref ref-type="bibr" rid="CR14">14</xref>]. At our knowledge, there are not studies investigating these effects in a population of T2DM failing heart subjects. Moreover, our study hypothesis was that, in T2DM failing heart patients multipolar LV pacing may lead to a reduction of PNS episodes, LV leads dislodgments, and interventions to re-positioning LV leads as compared to bipolar LV pacing. These beneficial effects may be associated to a significant reduction of arrhythmic events, hospitalizations for HF worsening, cardiac deaths, and all cause deaths in T2DM patients. Therefore, the aim of the study was to investigate these effects in a population of T2DM failing heart patients randomly treated by CRT-d via multipolar LV lead vs bipolar LV lead. In T2DM failing heart patients, CRT-d via multipolar LV lead vs bipolar LV lead may induce an amelioration of the HF clinical status, and of the CRT-d responders rate.</p></sec><sec id="Sec2"><title>Methods</title><p>From September 2012 to September 2015 we conducted a multicenter, prospective, randomized study at University of Campania Luigi Vanvitelli, Italy, Catholic University of Sacred Heart, Campobasso, Italy, and John Paul II Research and Care Foundation, Campobasso, Italy. We screened 213 consecutive T2DM patients (<italic>screening phase</italic>) with stable chronic heart failure, New York Heart Association (NYHA) functional class II or III, left bundle branch block, severe left ventricle ejection fraction reduction (LVEF&#x000a0;&#x0003c;&#x000a0;35%), stable sinus rhythm, candidates to receive a CRT-d treatment according to the international guidelines [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>] (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Exclusion criteria were as follows: age&#x000a0;&#x0003c;18 or&#x000a0;&#x0003e;75&#x000a0;years, ejection fraction&#x000a0;&#x0003e;35%, previous implantable cardioverter defibrillator (ICD), CRT-d and/or pacemaker implant, absence of informed patient consent, and any condition that would make survival for 1&#x000a0;year unlikely. One hundred and ninety-nine eligible patients were included in the study, and received a CRT-d treatment, and a traditional CRT-d ambulatory monitoring (<italic>inclusion phase</italic>) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The CRT-d has randomly undergone via multipolar LV lead pacing (n 101) vs bipolar LV lead pacing (n 98) (<italic>intervention phase</italic>) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). We used a computer programming code for treatment randomization. Study population was then divided in multipolar CRT-d group (multipolar LV lead pacing), vs bipolar CRT-d group (bipolar LV lead pacing). Before interventions, baseline laboratory studies, including HbA1c, lipid panel, and fibrinogen, were determined. In this population two patients have refused to participate in the study, one have refused to receive a CRT-d, and one have been lost at follow up. Therefore, 99 patients in multipolar CRT group vs 96 patients in the bipolar CRT group completed the 12&#x000a0;months follow up (<italic>follow up phase</italic>) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Responders patients to a CRT-d treatment were defined by evidence of LV reverse remodeling, 6&#x000a0;min-walk improvement and Minnesota living with heart failure scale improvement as previous described [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Enrolled patients were followed by clinical, instrumental assessment, and device telemetric control (at implant, 10&#x000a0;days, 6th, and 12th months after discharge). During these visits, and device interrogations, we reported lead functionality parameters, and arrhythmic events in CRT-d recipients, PNS episodes, and subsequently CRT-d effect in terms of clinical outcomes, as CRT response entity, and clinical events. The study was conducted in accordance with the Declaration of Helsinki. The Ethics Committees of all participating institutions approved the protocol. All patients were informed about the study nature, and gave their written informed, and signed consent to participate in the study.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>In this figure study flow chart representation. The study was conducted by the following phases: screening phase, inclusion phase, intervention phase, follow up phase. In the screening phase, 213 consecutive T2DM patients [with chronic heart failure lasting for at least 3 months, New York Heart Association (NYHA) functional class II or III, left bundle brunch block, severe left ventricle ejection fraction reduction (LVEF&#x000a0;&#x0003c;&#x000a0;35%)], and an indication for cardiac resynchronization therapy with a defibrillator (CRT-d) treatment, were screened to be included in the study (see the inclusion and exclusion criteria in the text). In the inclusion phase 199 patients of this screened population were identified, and included for participation in this study (see inclusion and exclusion criteria in the text). This phase was followed by intervention phase, in that 199 patients received a CRT-d device implant. The CRT-d implant was randomly performed by multipolar (n 101 patients) vs bipolar (n 98 patients) left ventricle pacing lead. After the CRT-d treatment these patients were ambulatory monitored by clinical and instrumental assessment as described in the text during follow up phase. Nine nine patients in multipolar CRT group vs 96 patients in the bipolar CRT group completed the follow up (two patients have refused to participate in the study, one have refused to receive a CRT-d, and one have been lost at follow up)</p></caption><graphic xlink:href="12933_2017_554_Fig1_HTML" id="MO1"/></fig>
</p><sec id="Sec3"><title>Intervention phase</title><sec id="Sec4"><title>CRT-d implant procedure, and LV pacing leads positioning</title><p>Experienced electrophysiologists in CRT implantation performed the three CRT leads positioning in cardiac chambers, and then connected to the CRT-d generator. All CRT-d implant procedures were standardized. Right atrial catheters were all placed in right atrial appendage, and right ventricular catheters in right ventricle apex, as indicated by antero-posterior, right anterior, and left anterior oblique views projections at radioscopic imaging. LV epicardial catheters were placed by percutaneous coronary sinus catheterization in a lateral and/or posterior&#x02013;lateral target vessel [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. We randomly chose a multipolar and/or a bipolar LV pacing lead, as described before in the text. After reaching the target left epicardium vessel, we determined the final LV lead position and pacing configuration, by acceptability of pacing thresholds, absence of diaphragmatic stimulation, and anatomic position (chosen position in the target vessel). The final position of the LV pacing lead was assessed with cine fluoroscopy. Implantation duration was defined as the time between skin incision until suture. We used bipolar LV pacing leads (St Jude Medical, Sylmar, CA, USA; Medtronic, Minneapolis, MN, USA), and quadripolar LV pacing leads (Quartet<sup>&#x000ae;</sup> model 1458Q and Promote Q<sup>&#x000ae;</sup>, St Jude Medical, Sylmar, CA, USA; Attain Performa<sup>&#x000ae;</sup>model, Medtronic, Minneapolis, MN, USA), over-the-wire, steroid eluting with a in-line connector. LV pacing leads were connected to an appropriate bipolar CRT-D device (CRT-d device, St Jude Medical, Sylmar, CA, USA; Medtronic, Minneapolis, MN, USA), and/or to a quadripolar CRT-d device (Quadra Assura CRT-d device, St Jude Medical, Sylmar, CA, USA; Viva<sup>&#x000ae;</sup> Quad XT and Viva<sup>&#x000ae;</sup> Quad S cardiac CRT-d, Minneapolis, MN, USA).</p></sec></sec><sec id="Sec5"><title>Follow up phase</title><sec id="Sec6"><title>Lead functionality parameters</title><p>Right atrium, right ventricle, and left ventricle leads functionality parameters (sensing, impedance, and pacing thresholds) were measured as reported, and indicated by international guidelines [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. These parameters were P, and R-wave amplitude values (sensing thresholds), lead impedances values (impedance thresholds), and lead pacing outputs values (pacing thresholds) (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref>). We monitored, measured, and reported these three parameters according to author&#x02019;s suggestions [<xref ref-type="bibr" rid="CR17">17</xref>]. The sensing thresholds values, defined as P wave and R wave sensing amplitude, were obtained from the intra-cardiac electrograms records, measured using a sensing configuration [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. The pacing thresholds, and impedance thresholds values, were measured using pacing catheter configurations [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. To measure intra thoracic impedance (Ohm), and pacing thresholds (Volt for ms), we focused on the right ventricle (RV) coil electrode to device case pathway configuration, and on the left ventricle (LV) tip to LV ring configuration [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>In this figure the representation of cumulative survival events free curves for study endpoints, by Cox regression analysis curves. The figure is structured in seven parts, as <bold>a</bold>&#x02013;<bold>f</bold>, Fig. <xref rid="Fig3" ref-type="fig">3</xref>. In <italic>green color</italic> the bipolar group, in <italic>blue color</italic> the multipolar group for each figure part. The symbol <italic>asterisk</italic> was marking a statistical significant event, as indicated by a p value&#x000a0;&#x0003c;0.05. In the part <bold>a</bold> of the figure, the curve representation of Phrenic Nerve stimulation events as &#x0201c;cumulative risk for Phrenic Nerve stimulation&#x0201d; (on <italic>y axis</italic>) during 360&#x000a0;days follow up (on <italic>x axis</italic>) comparing multipolar vs bipolar group. In the part <bold>b</bold> of the figure, the curve representation of catheter dislocation events as &#x0201c;cumulative risk for catheter dislodgement events&#x0201d; (on <italic>y axis</italic>) during 360&#x000a0;days follow up (on <italic>x axis</italic>) comparing multipolar vs bipolar group. In the part <bold>c</bold> of the figure, the curve representation of re-interventions for left ventricle lead re-positioning after dislodgment as &#x0201c;cumulative risk for re-interventions for left ventricle catheter re-positioning&#x0201d; (on <italic>y axis</italic>) during 360&#x000a0;days follow up (on <italic>x axis</italic>) comparing multipolar vs bipolar group. In the part <bold>d</bold> of the figure, the curve representation of hospital admission events as &#x0201c;cumulative risk for hospital admissions events&#x0201d; (on <italic>y axis</italic>) during 360&#x000a0;days follow up (on <italic>x axis</italic>) comparing multipolar vs bipolar group. In the part <bold>e</bold> of the figure, the curve representation of atrial fibrillation events as &#x0201c;cumulative risk for atrial fibrillation events&#x0201d; (on <italic>y axis</italic>) during 360&#x000a0;days follow up (on <italic>x axis</italic>) comparing multipolar vs bipolar group. In the part <bold>f</bold> of the curve, the representation of all cause of deaths events as &#x0201c;cumulative risk for all cause of deaths events&#x0201d; (on y <italic>axis</italic>) during 360&#x000a0;days follow up (on <italic>x axis</italic>) comparing multipolar vs bipolar group</p></caption><graphic xlink:href="12933_2017_554_Fig2_HTML" id="MO2"/></fig>
<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>In this figure the representation of cumulative survival events free curves for study endpoints, by Cox regression analysis curves. In the part of the curve, the representation of cardiac deaths events as &#x0201c;cumulative risk for cardiac deaths events&#x0201d; (on <italic>y axis</italic>) during 360&#x000a0;days follow up (on <italic>x axis</italic>) comparing multipolar vs bipolar group</p></caption><graphic xlink:href="12933_2017_554_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec7"><title>Arrhythmic events in CRT-d recipients</title><p>In CRT-d patients we monitored and reported atrial fibrillation (AF), ventricular tachycardia (VT), and ventricular fibrillation (VF) episodes, and implantable cardioverter defibrillator (ICD) shocks. AF was defined as paroxysmal, and/or not paroxysmal according to authors&#x02019; suggestions [<xref ref-type="bibr" rid="CR20">20</xref>]. VT was defined as arrhythmia originating from ventricular chambers, sustained and/or not sustained by arrhythmic event duration [<xref ref-type="bibr" rid="CR21">21</xref>].VF was defined as a fibrillating arrhythmia originating from ventricular chambers, and associated to hemodynamic instability, and cardiac arrest [<xref ref-type="bibr" rid="CR21">21</xref>]. ICD shocks were defined as high energy interventions by CRT-d device to restore sinus rhythm during at risk of life sustained VT and or VF events [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p></sec><sec id="Sec8"><title>Phrenic nerve stimulation events</title><p>PNS and left ventricle pacing leads threshold were measured by a standard protocol at CRT-d implant, and during all follow up durations by CRT-d devices interrogations. We evaluated these parameters according to authors&#x02019; suggestions, and previous experiences [<xref ref-type="bibr" rid="CR22">22</xref>]. We tested PNS thresholds during respiratory phases, and supine, left lateral, right lateral, sitting, and standing body position, in each follow up phase, and for every patient. We accepted the pacing configuration (multipolar and bipolar CRT-d pacing) testing the absence of PNS at pacing output of 7.5&#x000a0;V, with a measured pacing threshold less than or equal to 2.5&#x000a0;V. In case of PNS diagnosis during follow up, by patients symptoms assessment, devices interrogations, and physician ambulatory diagnosis (clinical and instrumental PNS diagnosis), we reached the best left ventricle lead pacing configuration to solve PNS. This test was repeated in both clinical group (multipolar vs bipolar LV pacing lead) of CRT-d patients. In this way we reached the final biventricular pacing configuration by LV pacing lead configuration at best pacing thresholds, and in absence of PNS, and after evaluating the effects of different configurations on hemodynamic parameters, as indicated by authors [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec9"><title>LV leads dislodgments</title><p>LV catheter dislodgments resulted by the movement of the catheter into and out of the coronary sinus implantation vessel site, and then causing a change in the catheter tip location [<xref ref-type="bibr" rid="CR22">22</xref>]. LV catheter dislodgments event was diagnosed by patients clinical symptoms, hospital admissions schedules, hospital discharge schedules, and during medical interrogation at follow up visits. It resulted in altered sensing, pacing, and impedance thresholds of LV lead at device interrogations during follow up. LV catheter dislodgment was confirmed by radiographic biplane projections assessment [<xref ref-type="bibr" rid="CR22">22</xref>].</p></sec><sec id="Sec10"><title>CRT-d effect on clinical outcomes (interventions for LV lead re-positioning, CRT responders rate, and clinical events)</title><p>
<italic>CRT</italic>-<italic>d responders rate</italic> was evaluated by periodic clinical examination, and echocardiography assessment [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. <italic>Interventions for LV lead re</italic>-<italic>positioning</italic> were defined as interventions done after the first CRT-d implant [<xref ref-type="bibr" rid="CR22">22</xref>], and were evaluated by hospital admissions schedules, hospital discharge schedules, and during medical interrogation at follow up visits. These interventions were performed in case of LV catheter dislodgments. As other clinical outcomes, hospitalization rate was reported during telephonic interviews, by hospital admissions schedules, hospital discharge schedules, and during medical interrogation at follow up visits. <italic>Cardiac deaths, all cause of deaths, and stroke events</italic> were evaluated during office follow up visits 10&#x000a0;days after clinical discharge, and after 6th and 12th months by the treating physician, by telephonic interview, hospital admission, and discharge schedules. At each clinical follow-up, right atrial, right ventricular, and left ventricular leads functionality, <italic>atrial, and ventricular arrhythmias, ICD shocks</italic>, and biventricular pacing percentage, were evaluated and reported for each patient. NYHA classification was re-assessed, and patients graded their overall condition as unchanged or slightly, moderately, or markedly worsened, or improved since randomization by global self-assessment [<xref ref-type="bibr" rid="CR23">23</xref>]. All patients were instructed to report about devices alarms, loss of lead capture, <italic>phrenic nerve stimulation</italic>, and arrhythmias. All patients were instructed regularly to assess body weight, occurrence of dyspnea, and any clinical symptom. At each visit patients were asked whether medical events or symptoms suggestive of cardiac arrhythmias occurred, and an ECG, and an ECG Holter monitoring, were both performed to detect the presence of asymptomatic arrhythmias. Clinical evaluations included physical examination, vital signs, and review of adverse events. A fasting blood (at least 12&#x000a0;h from last meal) was performed for biochemical peripheral blood assay evaluation at every visit.</p></sec></sec><sec id="Sec11"><title>Study endpoints</title><p>As <italic>primary endpoints</italic> we monitored CRT-d effect in multipolar CRT-d patients vs bipolar CRT-d patients in terms of PNS episodes, LV leads dislodgments, interventions to re-position LV leads, hospitalization rate for HF worsening, cardiac deaths, and all cause deaths. As <italic>secondary endpoints</italic> we monitored CRT-d responders rate, AF events, VT events, VF events, ICD shocks, and strokes in both groups (multipolar CRT-d vs bipolar CRT-d patients).</p></sec><sec id="Sec12"><title>Statistical methods</title><p>A qualified statistician analyzed all collected data. The patients were divided before in multipolar CRT-d group vs bipolar CRT-d group, and during follow up visits, and controls in CRT-d responders vs CRT-d non-responders. We postulated that, the number of patients with alterations in primary and secondary endpoints was significantly different between multipolar CRT-d patients vs bipolar CRT-d patients. Safety analyses were performed on data from all enrolled patients. Continuous variables were expressed as means and standard deviations, and were tested by two-tailed Student t test for paired or unpaired data, as appropriate, or by one-way analysis of variance (ANOVA) for more than two independent groups of data. The categorical variables were compared by Chi square or Fisher exact test where appropriate. Survival analysis was performed with the use of the Kaplan&#x02013;Meier method. Predictors of the study endpoints were evaluated by using Cox regression models. A univariate analysis was conducted to examine the association between single principal clinic, echocardiographic, electrocardiographic characteristics, and multipolar LV pacing, and 12&#x000a0;months study outcomes, as catheter dislodgments, PNS events, re-intervention for catheter dislodgments, hospital admissions for heart failure worsening, and AF events. All variables with p value of less than 0.2 in the univariate analysis were subsequently entered into a multivariate model. In the multivariate model, variables were separately selected and a p value of less than 0.05 was considered significant. For all independent predictors, 95% confidence intervals were calculated. Statistical significance was considered for a p value of less than 0.05. The statistical analysis was performed using the SPSS software package for Windows 17.0 (SPSS Inc., Chicago Illinois).</p></sec></sec><sec id="Sec13"><title>Results</title><p>One hundred and ninety-five T2DM failing heart patients treated by a CRT-d completed the study follow up, 99 multipolar vs 95 bipolar CRT-d patients (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Mean population age was 67.4&#x000a0;&#x000b1;&#x000a0;6.5&#x000a0;years in overall population, 68.1&#x000a0;&#x000b1;&#x000a0;6.6 vs 66.9&#x000a0;&#x000b1;&#x000a0;6.4&#x000a0;years comparing multipolar vs bipolar CRT-d patients (p value&#x000a0;&#x0003e;0.05) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). One hundred and forty-four patients (74%) in overall population, and 71 (72%) vs 73 (76%) patients comparing multipolar vs bipolar CRT-d patients were males (p value&#x000a0;&#x0003e;0.05) (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Other clinical characteristics, echocardiographic parameters, and drug therapy at enrolment were similar, and balanced between two groups of patients (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Not differently from these results, we reported similar procedural data as skin to skin time (183&#x000a0;&#x000b1;&#x000a0;113 vs 179&#x000a0;&#x000b1;&#x000a0;116&#x000a0;min, p value&#x000a0;&#x0003e;0.05), fluoro time (17&#x000a0;&#x000b1;&#x000a0;4.7 vs 18&#x000a0;&#x000b1;&#x000a0;5.6&#x000a0;min, p value&#x000a0;&#x0003e;0.05), and CS cannulation time (14&#x000a0;&#x000b1;&#x000a0;5.4 vs 15&#x000a0;&#x000b1;&#x000a0;4.7&#x000a0;min, p value&#x000a0;&#x0003e;0.05), and CRT-d leads functionality parameters (left ventricle, right atrial, and right ventricular leads) comparing multipolar vs bipolar CRT-d patients (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). During follow up, primary and secondary study endpoints were reported in study population, comparing multipolar to bipolar CRT-d patients (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). At follow up, there was a statistical significant difference comparing multipolar to bipolar CRT-d patients, about phrenic nerve stimulation events [5 (5%) vs 18 (18.7%), p value 0.007], catheter displacement events [1 (1%) vs 9 (9.4%), p value 0018], and re-interventions for left leads re-positioning [1 (1%) vs 9 (9.4%), p value 0.018], hospitalizations for heart failure worsening [15 (15.2% vs 24 (25%), p value 0.046], and atrial fibrillation events [7 (7%) vs 16 (16.7%), p value 0.019] (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). At multivariate analysis, quadripolar LV lead vs bipolar LV lead pacing was associated to a reduction of LV catheter dislodgments in a percentage of more than 88% (HR 0.112 [0.014&#x02013;0.893], 95% CI, p value 0.039), and of 75% for phrenic nerve stimulations events (HR 0.246, [0.088&#x02013;0.686], 95% CI, p value 0.007) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Multipolar LV pacing reduced at more than 88% the cases of re-interventions for LV lead re-positioning (HR 0.112 [0.014&#x02013;0.893], 95% CI, p value 0.039) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Multipolar LV lead vs bipolar LV pacing was associated to a reduction of hospital admissions for heart failure worsening in a percentage more than 48% (HR 0.516, [0.279&#x02013;0.955], 95% CI, p value 0.035) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Multipolar LV lead pacing was associated to a reduction of atrial fibrillation events in a percentage of more than 73% (HR 0.261 [0.086&#x02013;0.794], 95% CI, p value 0.018) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). On the contrary, obesity was associated to increased risk to have atrial fibrillation events (HR 1.36, [1.09&#x02013;1.88], 95% CI, p value 0.02) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline data of the study cohort (clinical characteristics, echocardiographic parameters, and drug therapy)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">Overall</th><th align="left">Multipolar group</th><th align="left">Bipolar group</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left" colspan="5">Clinical characteristics</td></tr><tr><td align="left">&#x000a0;Patients n</td><td align="left">195</td><td align="left">99</td><td align="left">96</td><td align="left"/></tr><tr><td align="left">&#x000a0;Age, years</td><td align="left">67.4&#x000a0;&#x000b1;&#x000a0;6.5</td><td align="left">68.1&#x000a0;&#x000b1;&#x000a0;6.6</td><td align="left">66.9&#x000a0;&#x000b1;&#x000a0;6.4</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Male, n (%)</td><td align="left">144 (74%)</td><td align="left">71 (72%)</td><td align="left">73 (76%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Smokers (%)</td><td align="left">102 (52.3%)</td><td align="left">52 (52.5%)</td><td align="left">50 (52%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Dyslipidemia (%)</td><td align="left">102 (52%)</td><td align="left">52 (53)</td><td align="left">50 (52)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Obesity</td><td align="left">12 (6.1%)</td><td align="left">7 (7%)</td><td align="left">5 (5.2%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Hypertension</td><td align="left">136 (69.7%)</td><td align="left">71 (71.7%)</td><td align="left">65 (67.7%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Renal insufficiency (%)</td><td align="left">18 (9.2%)</td><td align="left">10 (10.1%)</td><td align="left">8 (8.3%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Ischemic HF (%)</td><td align="left">128 (65.6%)</td><td align="left">67 (68%)</td><td align="left">61 (63.5%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Non ischemic HF (idiopathic, hypertensive, or valvular) (%)</td><td align="left">67 (34.4%)</td><td align="left">32 (32.2%)</td><td align="left">35 (36.4%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Previous cardiac surgery (%)</td><td align="left">35 (18%)</td><td align="left">17 (18%)</td><td align="left">18 (19%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;NYHA II (%)</td><td align="left">102 (52.3%)</td><td align="left">53 (53.5%)</td><td align="left">50 (52%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;NYHA III (%)</td><td align="left">93 (47.7%)</td><td align="left">49 (49.5%)</td><td align="left">44 (45.8%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;QRS duration</td><td align="left">136.4&#x000a0;&#x000b1;&#x000a0;7.8</td><td align="left">137.3&#x000a0;&#x000b1;&#x000a0;7.4</td><td align="left">135.3&#x000a0;&#x000b1;&#x000a0;8.1</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;6MWT</td><td align="left">244.1&#x000a0;&#x000b1;&#x000a0;39.8</td><td align="left">239.5&#x000a0;&#x000b1;&#x000a0;44.7</td><td align="left">248.7&#x000a0;&#x000b1;&#x000a0;33.8</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;NT-proBNP (pg/ml)</td><td align="left">2307&#x000a0;&#x000b1;&#x000a0;631</td><td align="left">2322&#x000a0;&#x000b1;&#x000a0;567</td><td align="left">2281&#x000a0;&#x000b1;&#x000a0;723</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Hb1Ac (mmol/mol)</td><td align="left">57.8&#x000a0;&#x000b1;&#x000a0;15.6</td><td align="left">57.2&#x000a0;&#x000b1;&#x000a0;15.3</td><td align="left">58.2&#x000a0;&#x000b1;&#x000a0;16.1</td><td align="left">n.s</td></tr><tr><td align="left" colspan="5">Echocardiographic parameters</td></tr><tr><td align="left">&#x000a0;LVEDv (ml)</td><td align="left">198&#x000a0;&#x000b1;&#x000a0;39</td><td align="left">196&#x000a0;&#x000b1;&#x000a0;31</td><td align="left">201&#x000a0;&#x000b1;&#x000a0;45</td><td align="left">n.s</td></tr><tr><td align="left">
<italic>&#x000a0;LVESv</italic> (ml)</td><td align="left">137&#x000a0;&#x000b1;&#x000a0;29</td><td align="left">135&#x000a0;&#x000b1;&#x000a0;23</td><td align="left">141&#x000a0;&#x000b1;&#x000a0;36</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;LVEF (%)</td><td align="left">27&#x000a0;&#x000b1;&#x000a0;5</td><td align="left">27&#x000a0;&#x000b1;&#x000a0;5</td><td align="left">28&#x000a0;&#x000b1;&#x000a0;4</td><td align="left">n.s</td></tr><tr><td align="left" colspan="5">Mitral regurgitation</td></tr><tr><td align="left">&#x000a0;+</td><td align="left">91 (46.7%)</td><td align="left">44 (44.4%)</td><td char="." align="char">47(49%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;++</td><td align="left">77 (39.5%)</td><td align="left">40 (40.4%)</td><td align="left">37 (38.5%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;+++</td><td align="left">19 (9.7%)</td><td align="left">9 (9.1%)</td><td align="left">10 (10.4%)</td><td align="left">n.s</td></tr><tr><td align="left" colspan="5">Drug therapy</td></tr><tr><td align="left">&#x000a0;ACE-i/ARB</td><td align="left">170 (87.2%)</td><td align="left">86 (86.8%)</td><td align="left">84 (87.5%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Beta blockers</td><td align="left">137 (70.3%)</td><td align="left">70 (71%)</td><td align="left">67 (69.8%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Diuretics</td><td align="left">117 (60%)</td><td align="left">58 (58.6%)</td><td align="left">59 (61.5%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Digoxin</td><td align="left">43 (22%)</td><td align="left">21 (21.2%)</td><td align="left">22 (22.9%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Statins</td><td align="left">113 (57.9%)</td><td align="left">56 (56.6%)</td><td align="left">57 (59.4%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Insulin</td><td align="left">72 (36.9%)</td><td align="left">35 (35.3%)</td><td align="left">37 (38.5%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Oral hypoglycemic drugs</td><td align="left">131 (67.2%)</td><td align="left">68 (68.7%)</td><td align="left">63 (66%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Anti platelets drugs</td><td align="left">130 (66.7%)</td><td align="left">64 (63.6%)</td><td align="left">65 (67.7%)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Dicumarolic anticoagulants</td><td align="left">18 (9.2%)</td><td align="left">9 (9%)</td><td align="left">9 (9.4%)</td><td align="left">n.s</td></tr></tbody></table><table-wrap-foot><p>In this table clinical characteristics, drug therapy and echocardiographic parameters have been reported, at baseline, of overall population, and then comparing multipolar vs bipolar group of patients. Statistical analysis has been conducted, to compare categorical data, with the exact Pearson&#x02019;s &#x003a7;<sup>2</sup> test. We considered a two-sided p value of less than 0.05 as statistically significant. The &#x0201c;n.s&#x0201d; was for statistical not significant (p value&#x000a0;&#x0003e;0.05)</p><p>
<italic>ACE-i</italic> angiotensin converting enzyme inhibitor, <italic>ARB</italic> angiotensin receptor II blockers, <italic>COPD</italic> chronic obstructive pulmonary diseases, <italic>Hb1Ac</italic> glycosylated hemoglobin, <italic>y</italic> year, <italic>n</italic> number, <italic>LVEDv</italic> left ventricle end diastolic volume, <italic>LVESv</italic> left ventricle end systolic volume, <italic>LVEF</italic> left ventricle ejection fraction, <italic>6MWT</italic> 6 min walking test, n is for number, <italic>NYHA</italic> New York Hearth Association, <italic>NOACs</italic> new oral anti coagulations drugs, <italic>n.sis</italic> not statistical significant (p value &#x0003e;0.05), <italic>NT-proBNP</italic> N terminal pro B type Natriuretic peptide, in mitral regurgitation the symbol +, ++, +++ indicating low grade (+), mild grade (++), and more than mild (+++) regurgitation grade</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Procedural data of the study cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameters</th><th align="left">Quadripolar group (n 99)</th><th align="left">Bipolar group (n 96)</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left">Skin to skin time</td><td align="left">183&#x000a0;&#x000b1;&#x000a0;113</td><td align="left">179&#x000a0;&#x000b1;&#x000a0;116</td><td align="left">n.s</td></tr><tr><td align="left">Fluoro time</td><td align="left">17&#x000a0;&#x000b1;&#x000a0;4.7</td><td align="left">18&#x000a0;&#x000b1;&#x000a0;5.6</td><td align="left">n.s</td></tr><tr><td align="left">CS cannulation time</td><td align="left">14&#x000a0;&#x000b1;&#x000a0;5.4</td><td align="left">15&#x000a0;&#x000b1;&#x000a0;4.7</td><td align="left">n.s</td></tr><tr><td align="left" colspan="4">CS target vessel</td></tr><tr><td align="left">&#x000a0;Anterior, n (%)</td><td align="left">3 (3)</td><td align="left">3 (3)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Anterolateral, n (%)</td><td align="left">13 (13)</td><td align="left">11 (12)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Lateral, n (%)</td><td align="left">51 (51)</td><td align="left">52 (54)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Postero-lateral, n (%)</td><td align="left">28 (28)</td><td align="left">25 (26)</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Posterior, n (%)</td><td align="left">4 (4)</td><td align="left">5 (5)</td><td align="left">n.s</td></tr><tr><td align="left" colspan="4">LV lead parameters</td></tr><tr><td align="left">&#x000a0;Impedance thresholds</td><td align="left">761&#x000a0;&#x000b1;&#x000a0;182</td><td align="left">685&#x000a0;&#x000b1;&#x000a0;196</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Pacing thresholds</td><td align="left">0.5&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="left">0.5&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Sensing thresholds</td><td align="left">14&#x000a0;&#x000b1;&#x000a0;7.2</td><td align="left">13.4&#x000a0;&#x000b1;&#x000a0;7.3</td><td align="left">n.s</td></tr><tr><td align="left" colspan="4">RA lead parameters</td></tr><tr><td align="left">&#x000a0;Impedance thresholds</td><td align="left">438&#x000a0;&#x000b1;&#x000a0;164</td><td align="left">452&#x000a0;&#x000b1;&#x000a0;133</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Pacing thresholds</td><td align="left">0.4&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left">0.5&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Sensing thresholds</td><td align="left">2.1&#x000a0;&#x000b1;&#x000a0;1.7</td><td align="left">2.3&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="left">n.s</td></tr><tr><td align="left" colspan="4">RV lead parameters</td></tr><tr><td align="left">&#x000a0;Impedance thresholds</td><td align="left">581&#x000a0;&#x000b1;&#x000a0;151</td><td align="left">577&#x000a0;&#x000b1;&#x000a0;163</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Shock impedance thresholds</td><td align="left">73&#x000a0;&#x000b1;&#x000a0;15</td><td align="left">76&#x000a0;&#x000b1;&#x000a0;14</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Pacing thresholds</td><td align="left">0.5&#x000a0;&#x000b1;&#x000a0;0.45</td><td align="left">0.43&#x000a0;&#x000b1;&#x000a0;0.35</td><td align="left">n.s</td></tr><tr><td align="left">&#x000a0;Sensing thresholds</td><td align="left">19&#x000a0;&#x000b1;&#x000a0;6</td><td align="left">18&#x000a0;&#x000b1;&#x000a0;5</td><td align="left">n.s</td></tr></tbody></table><table-wrap-foot><p>In this table we reported procedural data as functionality parameters of devices leads (left ventricle, right atrium, and right ventricle leads), and procedural times at implant (shin to skin time, fluoro time, CS target vessel, and CS cannulation time) comparing multipolar vs bipolar group of patients. Impedance thresholds are expressed in Ohm. Pacing thresholds are expressed in millivolts for milliseconds. Sensing thresholds are expressed in millivolts. Procedural times (skin to skin time, fluoro time, and CS cannulation time) are expressed in minutes. The &#x0201c;n.s&#x0201d; was for statistical not significant (p value&#x000a0;&#x0003e;0.05)</p><p>
<italic>CS</italic> coronary sinus, <italic>LV</italic> left ventricle, <italic>RA</italic> right atrium, <italic>RV</italic> right ventricle</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Clinical events of the study cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Clinical events</th><th align="left">Overall (n 195)</th><th align="left">Quadripolar group (n 99)</th><th align="left">Bipolar group (n 96)</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left">CRT-d responders rate (%)</td><td char="(" align="char">117 (60%)</td><td char="(" align="char">61 (61.6%)</td><td char="(" align="char">56 (58%)</td><td char="." align="char">0.27</td></tr><tr><td align="left">Phrenic nerve stimulation</td><td char="(" align="char">23 (11.8%)</td><td char="(" align="char">5 (5%)</td><td char="(" align="char">18 (18.7%)</td><td char="." align="char">0.007*</td></tr><tr><td align="left">Catheter displacement</td><td char="(" align="char">10 (5.1%)</td><td char="(" align="char">1 (1%)</td><td char="(" align="char">9 (9.4%)</td><td char="." align="char">0.018*</td></tr><tr><td align="left">Re-interventions</td><td char="(" align="char">10 (5.1%)</td><td char="(" align="char">1 (1%)</td><td char="(" align="char">9 (9.4%)</td><td char="." align="char">0.018*</td></tr><tr><td align="left">Hospitalizations for HF worsening</td><td char="(" align="char">39 (20%)</td><td char="(" align="char">15 (15.2%)</td><td char="(" align="char">24 (25%)</td><td char="." align="char">0.046*</td></tr><tr><td align="left">Stroke</td><td char="(" align="char">4 (2%)</td><td char="(" align="char">2 (2%)</td><td char="(" align="char">2 (2%)</td><td char="." align="char">0.62</td></tr><tr><td align="left">AF n</td><td char="(" align="char">21 (10.8%)</td><td char="(" align="char">7 (7%)</td><td char="(" align="char">16 (16.7%)</td><td char="." align="char">0.019*</td></tr><tr><td align="left">VT n</td><td char="(" align="char">51 (26.1%)</td><td char="(" align="char">25 (25.2%)</td><td char="(" align="char">26 (27.1%)</td><td char="." align="char">0.5</td></tr><tr><td align="left">ICD shocks</td><td char="(" align="char">27 (13.8%)</td><td char="(" align="char">13 (13.1%)</td><td char="(" align="char">14 (14.6%)</td><td char="." align="char">0.51</td></tr><tr><td align="left">Cardiac deaths</td><td char="(" align="char">9 (5.6%)</td><td char="(" align="char">4 (4%)</td><td char="(" align="char">5 (5.2%)</td><td char="." align="char">0.43</td></tr><tr><td align="left">All cause deaths</td><td char="(" align="char">12 (6.2%)</td><td char="(" align="char">5 (5%)</td><td char="(" align="char">7 (7.3%)</td><td char="." align="char">0.33</td></tr><tr><td align="left">Stroke</td><td char="(" align="char">5 (2.6%)</td><td char="(" align="char">2 (2%)</td><td char="(" align="char">3 (3.1%)</td><td char="." align="char">0.36</td></tr></tbody></table><table-wrap-foot><p>In this table are reported clinical events after the CRT-d implant in quadripolar vs bipolar group</p><p>
<italic>AF</italic> atrial fibrillation, <italic>CRT-d</italic> cardiac resynchronization therapy with a defibrillator, <italic>HF</italic> heart failure, <italic>ICD</italic> internal cardioverter defibrillator, <italic>VT</italic> ventricular tachycardia</p><p>The symbol * was marking a statistical significant value, as p value&#x000a0;&#x0003c;0.05</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Univariate and multivariate analysis of predictive factors of the study cohort outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">HR</th><th align="left">Univariate (95 % CI)</th><th align="left">p value</th><th align="left">HR</th><th align="left">Multivariate (95 % CI)</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left" colspan="7">A. Catheter dislodgments</td></tr><tr><td align="left">&#x000a0;Age</td><td char="." align="char">0.902</td><td char="(" align="char">[0.807&#x02013;1.008]</td><td char="." align="char">0.068</td><td char="." align="char">0.866</td><td char="(" align="char">[0.741&#x02013;1.013]</td><td char="." align="char">0.072</td></tr><tr><td align="left">&#x000a0;Obesity</td><td char="." align="char">1.718</td><td char="(" align="char">[0.218&#x02013;3.568]</td><td char="." align="char">0.608</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Renal dysfunction</td><td char="." align="char">1.073</td><td char="(" align="char">[0.136&#x02013;4.873]</td><td char="." align="char">0.946</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;NYHA 3</td><td char="." align="char">0.417</td><td char="(" align="char">[0.108&#x02013;1.612]</td><td char="." align="char">0.205</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;QRS duration</td><td char="." align="char">0.962</td><td char="(" align="char">[0.872&#x02013;1.061]</td><td char="." align="char">0.437</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;LVEF</td><td char="." align="char">1.072</td><td char="(" align="char">[0.928&#x02013;1.237]</td><td char="." align="char">0.345</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Quadripolar LV</td><td char="." align="char">5.278</td><td char="(" align="char">[1.175&#x02013;7.32]</td><td char="." align="char">0.035*</td><td char="." align="char">0.112</td><td char="(" align="char">[0.014&#x02013;0.893]</td><td char="." align="char">0.039*</td></tr><tr><td align="left" colspan="7">B. Phrenic nerve stimulation</td></tr><tr><td align="left">&#x000a0;Age</td><td char="." align="char">1.024</td><td char="(" align="char">[0.962&#x02013;1.089]</td><td char="." align="char">0.458</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Obesity</td><td char="." align="char">2.604</td><td char="(" align="char">[0.773&#x02013;8.767]</td><td char="." align="char">0.122</td><td char="." align="char">0.658</td><td char="(" align="char">[0.144&#x02013;3.01]</td><td char="." align="char">0.59</td></tr><tr><td align="left">&#x000a0;Renal dysfunction</td><td char="." align="char">0.043</td><td char="(" align="char">[0.02&#x02013;1.79]</td><td char="." align="char">0.306</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;NYHA 3</td><td char="." align="char">2.94</td><td char="(" align="char">[2.6&#x02013;4.9]</td><td char="." align="char">0.001*</td><td char="." align="char">0.97</td><td char="(" align="char">[0.022&#x02013;0.423]</td><td char="." align="char">0.2</td></tr><tr><td align="left">&#x000a0;QRS duration</td><td char="." align="char">1.019</td><td char="(" align="char">[0.975&#x02013;1.065]</td><td char="." align="char">0.405</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;LVEF</td><td char="." align="char">1.012</td><td char="(" align="char">[0.93&#x02013;1.101]</td><td char="." align="char">0.79</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Quadripolar LV</td><td char="." align="char">3.783</td><td char="(" align="char">[1.404&#x02013;10.191]</td><td char="." align="char">0.008*</td><td char="." align="char">0.246</td><td char="(" align="char">[0.088&#x02013;0.686]</td><td char="." align="char">0.007*</td></tr><tr><td align="left" colspan="7">C. Re-intervention for catheter dislodgments</td></tr><tr><td align="left">&#x000a0;Age</td><td char="." align="char">0.902</td><td char="(" align="char">[0.807&#x02013;1.008]</td><td char="." align="char">0.068</td><td char="." align="char">0.866</td><td char="(" align="char">[0.741&#x02013;1.013]</td><td char="." align="char">0.072</td></tr><tr><td align="left">&#x000a0;Obesity</td><td char="." align="char">1.718</td><td char="(" align="char">[0.218&#x02013;3.568]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Renal dysfunction</td><td char="." align="char">1.073</td><td char="(" align="char">[0.136&#x02013;4.873]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;NYHA 3</td><td char="." align="char">0.417</td><td char="(" align="char">[0.108&#x02013;1.612]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;QRS duration</td><td char="." align="char">0.962</td><td char="(" align="char">[0.872&#x02013;1.061]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;LVEF</td><td char="." align="char">1.072</td><td char="(" align="char">[0.928&#x02013;1.237]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Quadripolar LV</td><td char="." align="char">5.278</td><td char="(" align="char">[1.175&#x02013;7.32]</td><td char="." align="char">0.035*</td><td char="." align="char">0.112</td><td char="(" align="char">[0.014&#x02013;0.893]</td><td char="." align="char">0.039*</td></tr><tr><td align="left" colspan="7">D. Hospital admission for heart failure worsening</td></tr><tr><td align="left">&#x000a0;Age</td><td char="." align="char">0.823</td><td char="(" align="char">[0.961&#x02013;1.051]</td><td char="." align="char">0.823</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Obesity</td><td char="." align="char">1.062</td><td char="(" align="char">[0.33&#x02013;3.419]</td><td char="." align="char">0.92</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Renal &#x000a0;dysfunction</td><td char="." align="char">0.898</td><td char="(" align="char">[0.322&#x02013;2.501]</td><td char="." align="char">0.836</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;NYHA 3</td><td char="." align="char">1.667</td><td char="(" align="char">[0.926&#x02013;3.01]</td><td char="." align="char">0.089</td><td char="." align="char">0.624</td><td char="(" align="char">[0.326&#x02013;1.193]</td><td char="." align="char">0.154</td></tr><tr><td align="left">&#x000a0;QRS duration</td><td char="." align="char">1.019</td><td char="(" align="char">[0.983&#x02013;1.056]</td><td char="." align="char">0.3</td><td char="." align="char">1.012</td><td char="(" align="char">[0.973&#x02013;1.052]</td><td char="." align="char">0.559</td></tr><tr><td align="left">&#x000a0;LVEF</td><td char="." align="char">0.98</td><td char="(" align="char">[0.926&#x02013;1.038]</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Quadripolar LV</td><td char="." align="char">1.683</td><td char="(" align="char">[1.04&#x02013;3.03]</td><td char="." align="char">0.05</td><td char="." align="char">0.516</td><td char="(" align="char">[0.279&#x02013;0. 955]</td><td char="." align="char">0.035*</td></tr><tr><td align="left" colspan="7">E. Atrial fibrillation events</td></tr><tr><td align="left">&#x000a0;Age</td><td char="." align="char">1.031</td><td char="(" align="char">[0.968&#x02013;1.099]</td><td char="." align="char">0.343</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Obesity</td><td char="." align="char">5.571</td><td char="(" align="char">[2.038&#x02013;15.232]</td><td char="." align="char">0.001*</td><td char="." align="char">1.36</td><td char="(" align="char">[1.09&#x02013;1.88]</td><td char="." align="char">0.02*</td></tr><tr><td align="left">&#x000a0;Renal dysfunction</td><td char="." align="char">0.992</td><td char="(" align="char">[0.231&#x02013;4.257]</td><td char="." align="char">0.991</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;NYHA 3</td><td char="." align="char">2.58</td><td char="(" align="char">[1.001&#x02013;6.649]</td><td char="." align="char">0.05*</td><td char="." align="char">0.557</td><td char="(" align="char">[0.195&#x02013;1.591]</td><td char="." align="char">0.274</td></tr><tr><td align="left">&#x000a0;QRS duration</td><td char="." align="char">1.018</td><td char="(" align="char">[0.971&#x02013;1.067]</td><td char="." align="char">0.457</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;LVEF</td><td char="." align="char">1.043</td><td char="(" align="char">[0.95&#x02013;1.146]</td><td char="." align="char">0.375</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Quadripolar LV</td><td char="." align="char">3.29</td><td char="(" align="char">[1.205&#x02013;8.982]</td><td char="." align="char">0.02*</td><td char="." align="char">0.261</td><td char="(" align="char">[0.086&#x02013;0.794]</td><td char="." align="char">0.018*</td></tr><tr><td align="left" colspan="7">F. All cause deaths</td></tr><tr><td align="left">&#x000a0;Age</td><td char="." align="char">1.138</td><td char="(" align="char">[1.04&#x02013;1.246]</td><td char="." align="char">0.05*</td><td char="." align="char">1.149</td><td char="(" align="char">[0.89&#x02013;1.288]</td><td char="." align="char">0.058</td></tr><tr><td align="left">&#x000a0;Obesity</td><td char="." align="char">2.5</td><td char="(" align="char">[0.9&#x02013;2.91]</td><td char="." align="char">0.986</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Renal dysfunction</td><td char="." align="char">0.88</td><td char="(" align="char">[0.108&#x02013;7.193]</td><td char="." align="char">0.905</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;NYHA 3</td><td char="." align="char">1.471</td><td char="(" align="char">[0.276&#x02013;7.759]</td><td char="." align="char">0.649</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;QRS duration</td><td char="." align="char">1.051</td><td char="(" align="char">[0.984&#x02013;1.123]</td><td char="." align="char">0.141</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;LVEF</td><td char="." align="char">1.069</td><td char="(" align="char">[0.914&#x02013;1.249]</td><td char="." align="char">0.404</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Quadripolar LV</td><td char="." align="char">0.415</td><td char="(" align="char">[0.104&#x02013;1.659]</td><td char="." align="char">0.214</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="7">G. Cardiac deaths</td></tr><tr><td align="left">&#x000a0;Age</td><td char="." align="char">1.3</td><td char="(" align="char">[1.185&#x02013;1.426]</td><td char="." align="char">0.01*</td><td char="." align="char">1.332</td><td char="(" align="char">[0.858&#x02013;1.532]</td><td char="." align="char">0.056</td></tr><tr><td align="left">&#x000a0;Obesity</td><td char="." align="char">0.7</td><td char="(" align="char">[0.2&#x02013;2.896]</td><td char="." align="char">0.168</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Renal dysfunction</td><td char="." align="char">1.676</td><td char="(" align="char">[0.2&#x02013;14.02]</td><td char="." align="char">0.633</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;NYHA 3</td><td char="." align="char">0.386</td><td char="(" align="char">[0.069&#x02013;2.164]</td><td char="." align="char">0.279</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;QRS duration</td><td char="." align="char">0.932</td><td char="(" align="char">[0.806&#x02013;1.078]</td><td char="." align="char">0.342</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;LVEF</td><td char="." align="char">0.912</td><td char="(" align="char">[0.815&#x02013;1.044]</td><td char="." align="char">0.201</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Quadripolar LV</td><td char="." align="char">0.521</td><td char="(" align="char">[0.154&#x02013;1.758]</td><td char="." align="char">0.293</td><td align="left"/><td align="left"/><td align="left"/></tr></tbody></table><table-wrap-foot><p>In this table the representation of study outcomes, as catheter dislodgments (A), phrenic nerve stimulation events (B), re-intervention for catheter dislodgments (C), hospital admissions for heart failure worsening (D), atrial fibrillation events (E), all cause deaths (F), and cardiac deaths (G), and multivariate predictive factors</p><p>We have used for statistical analysis, a 95% interval of confidence (IC), and a significant statistical p value, p&#x000a0;&#x0003c;&#x000a0;0.05. The symbol * was marking factor with a p value &#x0003c;0.05. To test the final statistical used model, we have performed the Hosmer and Lemeshow test, with a &#x003c7;&#x000b2;&#x000a0;=&#x000a0;2.775, and a p value&#x000a0;&#x0003c;0.05</p><p>
<italic>NYHA 3</italic> New York Heart Association third class, <italic>LVEF</italic> left ventricle ejection fraction, <italic>LV</italic> left ventricle</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec14"><title>Discussion</title><p>In our study the multipolar CRT-d pacing was found to be superior to the bipolar CRT-d pacing respect to the reduction of PNS events, LV leads dislodgment, re-interventions for LV leads dislodgments, hospitalizations for HF worsening, and AF events (Figs. <xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref>; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The analysis of the others study endpoints did not show differences between the two study groups with regard to cardiac deaths, all cause deaths, strokes, VT events, and ICDs shocks, and CRT-d responders rate (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). In literature less has been reported about the effect of diabetes mellitus on the risks of arrhythmias, and ICDs therapies [<xref ref-type="bibr" rid="CR24">24</xref>]. Moreover, although authors reported a significant excess of cardiac hospitalizations and mortality in the diabetic population, this higher risk is not related to arrhythmias and/or to a difference in the rate of ICD treatments [<xref ref-type="bibr" rid="CR24">24</xref>]. We reported a statistical significant reduction of <italic>PNS events</italic> in multipolar group vs bipolar group [n 5 (%) vs n 18 (18.7%), p value 0.007] (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). PNS is a challenging, and a relevant problem in failing heart patients treated by CRT-d [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>], reported in a percentage of 7&#x02013;14% patients treated by bipolar LV leads, and associated to the LV lead location [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. In fact, PNS is more common with the LV lead in the mid-apical, posterior and lateral sites, and less common with the LV lead in the anterior or basal site [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Multipolar CRT-d pacing may reduce PNS. Physicians may reach and pace the target coronary vessel, and the target LV wall segment, by a LV pacing from electrodes more far from the tip of the lead, that may be more anatomically closed to phrenic nerve course [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. In our study multipolar lead LV pacing was associated to a reduction of <italic>LV leads displacements</italic>, and subsequently of <italic>re</italic>-<italic>interventions</italic> to re-position LV leads [n 1 (1%) vs n 9 (9.4%), p value 0.018], as compared to bipolar LV pacing (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b, c). In the multivariate analysis, multipolar LV lead pacing was associated to a reduction of <italic>LV leads displacements</italic>, and subsequently of <italic>re</italic>-<italic>interventions</italic> to re-position LV lead, in a percentage of more than 88% (HR 0.112 [0.014&#x02013;0.893], 95% CI, p value 0.039) (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>b, c). The ability to perform a CRT-d implant may be related to the possibility to cannulate CS, and to reach the target CS vessel [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Sometimes, the anatomic position of coronary sinus vessel, the angle of origin of the vessel, the vessel size, and others variables may render difficult to select the target vessel, and it may consequently affect the stability of the implanted LV lead [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Other times, the best anatomical, and the consequent more stable position in the target vessel may be related to the position of the tip of LV lead more close to the course of the phrenic nerve, as discussed before, and/or more close to LV segments conditioning worse sensing and pacing thresholds [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Therefore, a more stable vessel position may sometimes condition the sensing and pacing LV thresholds and programming, while on the contrary the best sensing and pacing LV configuration may not result in the more stable position in the target vessel [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. This may lead to re-positioning of LV lead, in a more proximal position in the target vessel, and/or in a different cardiac vein [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. These events may be more common seen in bipolar LV leads as compared to multipolar LV leads, by the position of sensing, and pacing couple of poles in the tip of LV bipolar catheter. This may also condition catheter dislodgments after the implant [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. Both these conditions may lead to dislodgments, replacements, and re-interventions of LV leads. Multipolar LV pacing leads may offer a greater variety of sensing and pacing configurations from different sites within a coronary vein, as compared to bipolar pacing [<xref ref-type="bibr" rid="CR30">30</xref>]. Therefore, this may reduce LV dislodgments, and re-interventions, allowing optimal LV lead placement to maximize biventricular pacing at long term follow up [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Moreover, we may prefer the more stable anatomic position in the target vessel, without replacing more proximally the LV lead, and/or finding others veins to reach the best sensing and pacing thresholds and programming [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. These results were similarly addressed by authors in the overall population of failing heart patients treated by multipolar CRT-d pacing [<xref ref-type="bibr" rid="CR27">27</xref>]. We may speculate that, the placement of multipolar LV lead in a target LV epicardium vessel, because its anatomical stability, and the possibility to program multiple sensing and pacing thresholds, may result in a stable and continuous CRT-d pacing [<xref ref-type="bibr" rid="CR26">26</xref>]. Moreover, this may consequently impact on <italic>AF events, and hospitalizations for HF worsening</italic> (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d, e). In fact, we found that multipolar pacing vs bipolar pacing may lead to a significant reduction of AF events [n 7 (7%) vs 16 (16.7%), p value 0.019]. Intriguingly, the use of multipolar LV pacing during CRT-d implant may be predictive of lower AF events at follow up (HR 0.261 [0.086&#x02013;0.794], 95% CI, p value 0.018) (Figs.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, <xref rid="Fig3" ref-type="fig">3</xref>; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). This effect CRT-d induced has been discussed by different authors. In the CARE-HF study authors reported that, in sinus rhythm patients the global incidence of AF was similar in medical therapy alone as compared to CRT [<xref ref-type="bibr" rid="CR31">31</xref>]. On the contrary, others authors reported that CRT-d pacing might be associated with shorter duration of AF events [<xref ref-type="bibr" rid="CR32">32</xref>]. Therefore, the stable and continuous CRT-d pacing may reduce AF burden [<xref ref-type="bibr" rid="CR31">31</xref>]. Authors supported this hypothesis by the observation of reversal of left atrial remodeling CRT-d induced, and then associated to shorter duration of AF events during CRT-d pacing [<xref ref-type="bibr" rid="CR32">32</xref>]. Similarly, same authors showed that AF occurrence was associated with failing heart worsening [<xref ref-type="bibr" rid="CR32">32</xref>]. These data are in line with our study results. In our study we reported that the obesity was an independent predictor of AF events (HR 1.36 [1.09&#x02013;1.88], 95% CI, p value 0.02). As first, obesity may be associated to a hyper activation of inflammatory tone, and cytokines expression [<xref ref-type="bibr" rid="CR33">33</xref>], and to hyper activation of the sympathetic tone [<xref ref-type="bibr" rid="CR34">34</xref>]. The hyper activation of the sympathetic tone may render obese patients more vulnerable to pro-arrhythmic stimuli [<xref ref-type="bibr" rid="CR34">34</xref>]. These functional alterations may be consequently associated to structural abnormalities, as abnormal visceral fat deposition, which may lead to an augmentation of atrial arrhythmic burden [<xref ref-type="bibr" rid="CR35">35</xref>]. These alterations may condition AF burden, without impacting on VT burden [<xref ref-type="bibr" rid="CR36">36</xref>]. On the contrary, the higher stability of multipolar LV lead, and the consequent continuous biventricular pacing in a target segment of LV wall, may reduce AF events. Consequently the obesity did not diminish the clinical benefit of CRT-d to reduce risk for appropriate ICD therapy, as we observed in our study [<xref ref-type="bibr" rid="CR36">36</xref>].This effect, and the opportunity to program multiple LV pacing configurations, may be induced by multipolar pacing [<xref ref-type="bibr" rid="CR37">37</xref>]. The multipolar stable, and continuous biventricular pacing, may induce a stabilization effect on cellular membranes, ionic currents, and cardiac cells [<xref ref-type="bibr" rid="CR37">37</xref>]. This effect, reducing AF episodes PNS, LV lead dislodgments, and re-interventions to 
re-position LV leads, may be associated to a lowering of <italic>hospitalizations for HF worsening</italic> in T2DM failing heart patients [n 15 (15.2%) vs 24 (25%), p value 0.046], comparing multipolar pacing vs bipolar pacing (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d). This may be seen as important study result, and a relevant study message. This result may be seen as a strong data supporting our primary study hypothesis. In fact, it may confirm that, in T2DM failing heart patients the multipolar LV pacing is an advancement of CRT-d pacing safe to use, and that it may be associated to a significant reduction of hospitalizations for HF worsening. In fact, we observed that the choice and the utilization of a multipolar LV pacing lead during CRT-d implant may be an independent predictor factor of hospitalizations for HF worsening (HR 0.516 [0.279&#x02013;0.955], p value 0.035) in T2DM failing heart patients (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d). CRT-d reduces the risk of heart-failure events in patients with a low ejection fraction and wide QRS complex [<xref ref-type="bibr" rid="CR38">38</xref>], and this effect has been reported also in diabetic patients [<xref ref-type="bibr" rid="CR36">36</xref>]. CRT-d is a class 1 indication to reduce hospitalizations for HF worsening in failing heart diabetic patients, and also in failing heart non diabetic patients [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Actually, for the first time in literature we may report that, multipolar pacing vs bipolar pacing may significantly reduce hospitalizations for HF worsening in T2DM failing heart patients. Parallely, we may observe that, the choice of multipolar CRT-d pacing may be predictive of hospitalizations lowering for HF worsening in T2DM failing heart patients. In our study, the reduction of HF events induced by multipolar CRT-d pacing, was not associated to a reduction of the mortality (cardiac deaths, and all cause deaths). Similarly, multipolar CRT-d pacing in T2DM patients did not significantly improve the CRT-d responder&#x02019;s rate. These results have to be seen in the complexity of diabetes, and of its effect on failing heart disease, and on clinical outcomes in CRT-d recipients [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. All these results, such as the not significant improvement in the percentage of CRT-d responders, may be related to higher percentage of ischemic cardiac disease conditioning HF in T2DM patients, and then impacting on CRT-d response [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>].</p><sec id="Sec15"><title>Study limitations</title><p>This study had few limitations. As first, we examined a small percentage of T2DM failing heart patients treated by multipolar vs bipolar CRT-d, as compared to overall population. This was due to loss of patients during follow up, and to the low adherence of patients to the study protocol as discussed in results session. Second, this study was conducted at 12&#x000a0;months follow up time, and this short time follow up duration may affect the long term follow up prognosis, and primary and secondary clinical outcomes. Third, we have to report the paucity of clinical characteristics that would provide a more accurate comparison to clinical trial subjects. At last we have not investigated the molecular, and epigenetic aspects induced by T2DM in failing heart patients, and/or modulated by CRT-d. In fact, T2DM by an altered glucose homeostasis may induce electrophysiological changes, which leads to QRS prolongation, decreased conduction velocity and increased arrhythmogenesis, and this may condition clinical prognosis [<xref ref-type="bibr" rid="CR39">39</xref>]. We mentioned data about cardiac electrophysiology properties by CRT devices interrogations, examined, and collected during routine devices interrogations. We did not report data by continuous devices monitoring systems [<xref ref-type="bibr" rid="CR40">40</xref>]. This may be limiting for our analysis, because continuous monitoring of CRT-d devices may impact positively on clinical outcomes [<xref ref-type="bibr" rid="CR40">40</xref>]. We did not perform imaging examinations to support cases of left atrial remodeling observed in study population CRT, and associated to shorter duration of AF events as described by authors [<xref ref-type="bibr" rid="CR30">30</xref>]. In this study we did not perform animal experiments to test these clinical effect induced by multipolar CRT-d pacing in T2DM failing heart subjects, and we loss data about cardiac cells electrical properties, inflammatory tone, oxidative stress modulation, and sympathetic tone activity in T2DM patients. In this study we did not report data about the epigenetic effect CRT-d induced in T2DM failing heart patients, and this may be a limiting factor of our study analysis [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. In this study we did not compare multipolar Vs bipolar CRT-d pacing in failing heart diabetic vs non diabetic patients.</p></sec></sec><sec id="Sec16"><title>Conclusion</title><p>In T2DM failing heart patients multipolar CRT-d pacing may reduce PNS, catheters dislodgments, and re-interventions as compared to bipolar CRT-d pacing. This effect may be associated to reduction of AF events, and hospitalizations for HF worsening. Multipolar CRT-d pacing may offer a relevant hemodynamic advantage over a fixed conventional CRT-d pacing by a single site LV lead in failing heart patients [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. In our study, we focused on these hemodynamic, and clinical effects induced by multipolar CRT-d pacing in a population of T2DM failing heart patients. In fact, in T2DM failing heart patients multipolar LV pacing vs bipolar LV pacing may lead to a statistical significant reduction of hospital admissions for HF worsening. This study endpoint reached by multipolar CRT-d pacing, was not correlated to a statistical significant improvement of CRT-d responders rate in T2DM failing heart patients. Finally, multipolar CRT-d did not affect cardiac deaths, and all cause deaths in a population of T2DM failing heart patients. A part of this, we may speculate that, multipolar CRT-d pacing may represent a possible way to reduce CRT-d failures, and to improve clinical outcomes in T2DM failing heart patients. In fact, multipolar LV pacing may be predictive, as compared to bipolar pacing, of all these adverse procedure related events, and clinical events. We may speculate that, the lowering of AF events, and hospitalizations for HF worsening, and the predictably of these adverse conditions, may lead us to prefer a multipolar vs bipolar pacing in a population of T2DM failing heart patients. Moreover, we may propose multipolar CRT-d pacing as an innovative, and better treatment in T2DM failing heart patients.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AF</term><def><p>atrial fibrillation</p></def></def-item><def-item><term>CRP</term><def><p>C reactive protein</p></def></def-item><def-item><term>CRT-d</term><def><p>cardiac resynchronization therapy with a defibrillator</p></def></def-item><def-item><term>HF</term><def><p>heart failure</p></def></def-item><def-item><term>ICD</term><def><p>implantable cardioverter defibrillator</p></def></def-item><def-item><term>LV</term><def><p>left ventricle</p></def></def-item><def-item><term>LVEF</term><def><p>left ventricle ejection fraction</p></def></def-item><def-item><term>ms</term><def><p>millisecond</p></def></def-item><def-item><term>mV</term><def><p>millivolt</p></def></def-item><def-item><term>NYHA</term><def><p>New York Heart Association</p></def></def-item><def-item><term>PNS</term><def><p>phrenic nerve stimulation</p></def></def-item><def-item><term>RV</term><def><p>right ventricular</p></def></def-item><def-item><term>T2DM</term><def><p>type 2 diabetes mellitus</p></def></def-item><def-item><term>VF</term><def><p>ventricular fibrillation</p></def></def-item><def-item><term>VT</term><def><p>ventricular tachycardia</p></def></def-item></def-list></glossary><ack><title>Authors&#x02019; contributions</title><p>CS wrote the study protocol, collected, analyzed data, performed statistical analysis, and wrote the article. VG and AS collected data. RM and GP revised all the manuscript. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p>All authors have equally contributed to the study.</p></sec><sec id="FPar2"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p>Data and materials are available.</p></sec><sec id="FPar4"><title>Consent for publication</title><p>Authors give full consent for publication of the present article.</p></sec><sec id="FPar5"><title>Ethics approval and consent to participate</title><p>This study was conducted in accordance with the Declaration of Helsinki. The Ethics Committees of all participating institutions approved the protocol. All patients were informed about the study nature, and gave their written informed, and signed consent to participate in the study.</p></sec><sec id="FPar6"><title>Funding</title><p>This study was conducted without sponsors and without financial support.&#x000a0;C.S. receives a research Grant from European Society of Cardiology.</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>ES</given-names></name><name><surname>Laiteerapong</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>JY</given-names></name><name><surname>John</surname><given-names>PM</given-names></name><name><surname>Moffet</surname><given-names>HH</given-names></name><name><surname>Karter</surname><given-names>AJ</given-names></name></person-group><article-title>Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study</article-title><source>JAMA Intern Med</source><year>2014</year><volume>174</volume><issue>2</issue><fpage>251</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2013.12956</pub-id><pub-id pub-id-type="pmid">24322595</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Roman</surname><given-names>MJ</given-names></name><name><surname>Paranicas</surname><given-names>M</given-names></name><name><surname>O&#x02019;Grady</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>ET</given-names></name><name><surname>Welty</surname><given-names>TK</given-names></name><name><surname>Fabsitz</surname><given-names>RR</given-names></name><name><surname>Robbins</surname><given-names>D</given-names></name><name><surname>Rhoades</surname><given-names>ER</given-names></name><name><surname>Howard</surname><given-names>BV</given-names></name></person-group><article-title>Impact of diabetes on cardiac structure and function: the Strong Heart Study</article-title><source>Circulation</source><year>2000</year><volume>101</volume><fpage>2271</fpage><lpage>2276</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.101.19.2271</pub-id><pub-id pub-id-type="pmid">10811594</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kannel</surname><given-names>WB</given-names></name><name><surname>McGee</surname><given-names>DL</given-names></name></person-group><article-title>Diabetes and cardiovascular disease: the Framingham study</article-title><source>JAMA</source><year>1979</year><volume>241</volume><fpage>2035</fpage><lpage>2038</lpage><pub-id pub-id-type="doi">10.1001/jama.1979.03290450033020</pub-id><pub-id pub-id-type="pmid">430798</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lind</surname><given-names>M</given-names></name><name><surname>Bounias</surname><given-names>I</given-names></name><name><surname>Olsson</surname><given-names>M</given-names></name><name><surname>Gudbjornsdottir</surname><given-names>S</given-names></name><name><surname>Svenson</surname><given-names>AM</given-names></name><name><surname>Rosengren</surname><given-names>A</given-names></name></person-group><article-title>Glycaemic control and incidence of heart failure in 20985 patients with type 1 diabetes: an observational study</article-title><source>Lancet</source><year>2011</year><volume>378</volume><fpage>140</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(11)60471-6</pub-id><pub-id pub-id-type="pmid">21705065</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Jackson Hall</surname><given-names>W</given-names></name><name><surname>Cannom</surname><given-names>DS</given-names></name><name><surname>Klein</surname><given-names>H</given-names></name><name><surname>Brown</surname><given-names>MW</given-names></name><name><surname>James</surname><given-names>WS</given-names></name><name><surname>Daubert</surname><given-names>P</given-names></name><name><surname>Mark Estes</surname><given-names>NA</given-names></name><name><surname>Foster</surname><given-names>E</given-names></name><name><surname>Greenberg</surname><given-names>H</given-names></name><name><surname>Higgins</surname><given-names>SL</given-names></name><name><surname>Pfeffer</surname><given-names>MA</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Wilber</surname><given-names>D</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><collab>for the MADIT-CRT Trial Investigators*</collab></person-group><article-title>Cardiac-resynchronization therapy for the prevention of heart-failure events</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>1329</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0906431</pub-id><pub-id pub-id-type="pmid">19723701</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fantoni</surname><given-names>C</given-names></name><name><surname>Regoli</surname><given-names>F</given-names></name><name><surname>Ghanem</surname><given-names>A</given-names></name><name><surname>Raffa</surname><given-names>S</given-names></name><name><surname>Klersy</surname><given-names>C</given-names></name><name><surname>Sorgente</surname><given-names>A</given-names></name><name><surname>Faletra</surname><given-names>F</given-names></name><name><surname>Baravelli</surname><given-names>M</given-names></name><name><surname>Inglese</surname><given-names>L</given-names></name><name><surname>Salerno-Uriarte</surname><given-names>JA</given-names></name><name><surname>Klein</surname><given-names>HU</given-names></name><name><surname>Moccetti</surname><given-names>T</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name></person-group><article-title>Long-termoutcomein diabetic heart failure patients treated with cardiac resynchronization therapy</article-title><source>Eur J Heart Fail</source><year>2008</year><volume>10</volume><issue>3</issue><fpage>298</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.ejheart.2008.01.006</pub-id><pub-id pub-id-type="pmid">18296111</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>J</given-names></name><name><surname>Barsheshet</surname><given-names>A</given-names></name><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Martin</surname><given-names>D</given-names></name><name><surname>Ouellet</surname><given-names>G</given-names></name><name><surname>McNitt</surname><given-names>S</given-names></name><name><surname>Goldenberg</surname><given-names>I</given-names></name></person-group><article-title>Effectiveness of cardiac resynchronization therapy in diabetic patients with ischemic and nonischemic cardiomyopathy</article-title><source>Ann Non invasive Electrocardiol</source><year>2012</year><volume>2012</volume><issue>17</issue><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/j.1542-474X.2011.00476.x</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoppe</surname><given-names>UC</given-names></name><name><surname>Freemantle</surname><given-names>N</given-names></name><name><surname>Cleland</surname><given-names>JGF</given-names></name><name><surname>Marijianowski</surname><given-names>M</given-names></name><name><surname>Erdmann</surname><given-names>E</given-names></name></person-group><article-title>Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>722</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.2337/dc06-2035</pub-id><pub-id pub-id-type="pmid">17327349</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangiavacchi</surname><given-names>M</given-names></name><name><surname>Gasparini</surname><given-names>M</given-names></name><name><surname>Genovese</surname><given-names>S</given-names></name><name><surname>Pini</surname><given-names>D</given-names></name><name><surname>Klersy</surname><given-names>C</given-names></name><name><surname>Bragato</surname><given-names>R</given-names></name><name><surname>Andreuzzi</surname><given-names>B</given-names></name><name><surname>Municin&#x000f2;</surname><given-names>A</given-names></name><name><surname>Regoli</surname><given-names>F</given-names></name><name><surname>Galimberti</surname><given-names>P</given-names></name><name><surname>Ceriotti</surname><given-names>C</given-names></name><name><surname>Gronda</surname><given-names>E</given-names></name></person-group><article-title>Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy</article-title><source>Pacing Clin Electrophysiol</source><year>2008</year><volume>31</volume><fpage>1425</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8159.2008.01206.x</pub-id><pub-id pub-id-type="pmid">18950300</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruwald</surname><given-names>AC</given-names></name><name><surname>Schuger</surname><given-names>C</given-names></name><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Kutyifa</surname><given-names>V</given-names></name><name><surname>Olshansky</surname><given-names>B</given-names></name><name><surname>Greenberg</surname><given-names>H</given-names></name><name><surname>Cannom</surname><given-names>DS</given-names></name><name><surname>Estes</surname><given-names>NA</given-names></name><name><surname>Ruwald</surname><given-names>MH</given-names></name><name><surname>Huang</surname><given-names>DT</given-names></name><name><surname>Klein</surname><given-names>H</given-names></name><name><surname>McNitt</surname><given-names>S</given-names></name><name><surname>Beck</surname><given-names>CA</given-names></name><name><surname>Goldstein</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>MW</given-names></name><name><surname>Kautzner</surname><given-names>J</given-names></name><name><surname>Shoda</surname><given-names>M</given-names></name><name><surname>Wilber</surname><given-names>D</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name><name><surname>Daubert</surname><given-names>JP</given-names></name></person-group><article-title>Mortalityreduction in relation to implantable cardioverter defibrillator programming in the multicenter automatic defibrillator implantation trial-reduce inappropriate therapy (MADIT-RIT)</article-title><source>Circ: Arrhythm Electrophysiol</source><year>2014</year><volume>7</volume><issue>5</issue><fpage>785</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">25136077</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sardu</surname><given-names>C</given-names></name><name><surname>Marfella</surname><given-names>R</given-names></name><name><surname>Santulli</surname><given-names>G</given-names></name></person-group><article-title>Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people</article-title><source>J Cardiovasc Transl Res.</source><year>2014</year><volume>7</volume><issue>3</issue><fpage>362</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1007/s12265-014-9545-9</pub-id><pub-id pub-id-type="pmid">24500410</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Echouffo-Tcheugui</surname><given-names>JB</given-names></name><name><surname>Masoudi</surname><given-names>FA</given-names></name><name><surname>Bao</surname><given-names>H</given-names></name><name><surname>Spatz</surname><given-names>ES</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name></person-group><article-title>Diabetes mellitus and outcomes of cardiac resynchronization with implantable cardioverter-defibrillator therapy in older patients with heart failure</article-title><source>Circ Arrhythm Electrophysiol</source><year>2016</year><volume>9</volume><issue>8</issue><fpage>e004132</fpage><pub-id pub-id-type="doi">10.1161/CIRCEP.116.004132</pub-id><pub-id pub-id-type="pmid">27489243</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boriani</surname><given-names>G</given-names></name><name><surname>Connors</surname><given-names>S</given-names></name><name><surname>Kalarus</surname><given-names>Z</given-names></name><name><surname>Lemke</surname><given-names>B</given-names></name><name><surname>Mullens</surname><given-names>W</given-names></name><name><surname>Asensi</surname><given-names>JO</given-names></name><name><surname>Raatikainen</surname><given-names>P</given-names></name><name><surname>Gazzola</surname><given-names>C</given-names></name><name><surname>Farazi</surname><given-names>TG</given-names></name><name><surname>Leclercq</surname><given-names>C</given-names></name></person-group><article-title>Cardiac resynchronization therapy with a quadripolar electrode lead decreases complications at 6&#x000a0;months results of the MORE-CRT randomized trial</article-title><source>JACC: Clin Electrophysiol</source><year>2016</year><volume>2</volume><fpage>2</fpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osnat</surname><given-names>G</given-names></name><name><surname>Eyal</surname><given-names>N</given-names></name><name><surname>Shemy</surname><given-names>C</given-names></name><name><surname>David</surname><given-names>L</given-names></name><name><surname>Bar-Lev</surname><given-names>D</given-names></name><name><surname>Nechemya</surname><given-names>T</given-names></name><name><surname>Eldar</surname><given-names>M</given-names></name><name><surname>Glikson</surname><given-names>M</given-names></name></person-group><article-title>Programmable multiple pacing configurations help to overcome high left ventricular pacing thresholds and avoid phrenic nerve stimulation</article-title><source>Pacing Clin Electrophysiol</source><year>2005</year><volume>28</volume><issue>12</issue><fpage>1255</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8159.2005.00265.x</pub-id><pub-id pub-id-type="pmid">16403156</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>AE</given-names></name><name><surname>DiMarco</surname><given-names>JP</given-names></name><name><surname>Ellenbogen</surname><given-names>KA</given-names></name><name><surname>Estes</surname><given-names>NA</given-names><suffix>3rd</suffix></name><name><surname>Freedman</surname><given-names>RA</given-names></name><name><surname>Gettes</surname><given-names>LS</given-names></name><name><surname>Gillinov</surname><given-names>AM</given-names></name><name><surname>Gregoratos</surname><given-names>G</given-names></name><name><surname>Hammill</surname><given-names>SC</given-names></name><name><surname>Hayes</surname><given-names>DL</given-names></name><name><surname>Hlatky</surname><given-names>MA</given-names></name><name><surname>Newby</surname><given-names>LK</given-names></name><name><surname>Page</surname><given-names>RL</given-names></name><name><surname>Schoenfeld</surname><given-names>MH</given-names></name><name><surname>Silka</surname><given-names>MJ</given-names></name><name><surname>Stevenson</surname><given-names>LW</given-names></name><name><surname>Sweeney</surname><given-names>MO</given-names></name><name><surname>Tracy</surname><given-names>CM</given-names></name><name><surname>Epstein</surname><given-names>AE</given-names></name><name><surname>Darbar</surname><given-names>D</given-names></name><name><surname>DiMarco</surname><given-names>JP</given-names></name><name><surname>Dunbar</surname><given-names>SB</given-names></name><name><surname>Estes</surname><given-names>NA</given-names><suffix>3rd</suffix></name><name><surname>Ferguson</surname><given-names>TB</given-names><suffix>Jr</suffix></name><name><surname>Hammill</surname><given-names>SC</given-names></name><name><surname>Karasik</surname><given-names>PE</given-names></name><name><surname>Link</surname><given-names>MS</given-names></name><name><surname>Marine</surname><given-names>JE</given-names></name><name><surname>Schoenfeld</surname><given-names>MH</given-names></name><name><surname>Shanker</surname><given-names>AJ</given-names></name><name><surname>Silka</surname><given-names>MJ</given-names></name><name><surname>Stevenson</surname><given-names>LW</given-names></name><name><surname>Stevenson</surname><given-names>WG</given-names></name><name><surname>Varosy</surname><given-names>PD</given-names></name></person-group><article-title>American College of Cardiology Foundation.; American Heart Association Task Force on Practice Guidelines.; HeartRhythm Society. 2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>61</volume><issue>2</issue><fpage>e1</fpage><lpage>e6</lpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brignole</surname><given-names>M</given-names></name><name><surname>Auricchio</surname><given-names>A</given-names></name><name><surname>Baron-Esquivias</surname><given-names>G</given-names></name><name><surname>Bordachar</surname><given-names>P</given-names></name><name><surname>Boriani</surname><given-names>G</given-names></name><name><surname>Breithardt</surname><given-names>OA</given-names></name><name><surname>Cleland</surname><given-names>J</given-names></name><name><surname>Deharo</surname><given-names>JC</given-names></name><name><surname>Delgado</surname><given-names>V</given-names></name><name><surname>Elliott</surname><given-names>PM</given-names></name><name><surname>Gorenek</surname><given-names>B</given-names></name><name><surname>Israel</surname><given-names>CW</given-names></name><name><surname>Leclercq</surname><given-names>C</given-names></name><name><surname>Linde</surname><given-names>C</given-names></name><name><surname>Mont</surname><given-names>L</given-names></name><name><surname>Padeletti</surname><given-names>L</given-names></name><name><surname>Sutton</surname><given-names>R</given-names></name><name><surname>Vardas</surname><given-names>PE</given-names></name><collab>ESC Committee for Practice Guidelines (CPG)</collab><name><surname>Zamorano</surname><given-names>JL</given-names></name><name><surname>Achenbach</surname><given-names>S</given-names></name><name><surname>Baumgartner</surname><given-names>H</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Bueno</surname><given-names>H</given-names></name><name><surname>Dean</surname><given-names>V</given-names></name><name><surname>Deaton</surname><given-names>C</given-names></name><name><surname>Erol</surname><given-names>C</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Ferrari</surname><given-names>R</given-names></name><name><surname>Hasdai</surname><given-names>D</given-names></name><name><surname>Hoes</surname><given-names>AW</given-names></name><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Knuuti</surname><given-names>J</given-names></name><name><surname>Kolh</surname><given-names>P</given-names></name><name><surname>Lancellotti</surname><given-names>P</given-names></name><name><surname>Linhart</surname><given-names>A</given-names></name><name><surname>Nihoyannopoulos</surname><given-names>P</given-names></name><name><surname>Piepoli</surname><given-names>MF</given-names></name><name><surname>Ponikowski</surname><given-names>P</given-names></name><name><surname>Sirnes</surname><given-names>PA</given-names></name><name><surname>Tamargo</surname><given-names>JL</given-names></name><name><surname>Tendera</surname><given-names>M</given-names></name><name><surname>Torbicki</surname><given-names>A</given-names></name><name><surname>Wijns</surname><given-names>W</given-names></name><name><surname>Windecker</surname><given-names>S</given-names></name><collab>Document Reviewers</collab><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Blomstrom-Lundqvist</surname><given-names>C</given-names></name><name><surname>Badano</surname><given-names>LP</given-names></name><name><surname>Aliyev</surname><given-names>F</given-names></name><name><surname>B&#x000e4;nsch</surname><given-names>D</given-names></name><name><surname>Baumgartner</surname><given-names>H</given-names></name><name><surname>Bsata</surname><given-names>W</given-names></name><name><surname>Buser</surname><given-names>P</given-names></name><name><surname>Charron</surname><given-names>P</given-names></name><name><surname>Daubert</surname><given-names>JC</given-names></name><name><surname>Dobreanu</surname><given-names>D</given-names></name><name><surname>Faerestrand</surname><given-names>S</given-names></name><name><surname>Hasdai</surname><given-names>D</given-names></name><name><surname>Hoes</surname><given-names>AW</given-names></name><name><surname>Le Heuzey</surname><given-names>JY</given-names></name><name><surname>Mavrakis</surname><given-names>H</given-names></name><name><surname>McDonagh</surname><given-names>T</given-names></name><name><surname>Merino</surname><given-names>JL</given-names></name><name><surname>Nawar</surname><given-names>MM</given-names></name><name><surname>Nielsen</surname><given-names>JC</given-names></name><name><surname>Pieske</surname><given-names>B</given-names></name><name><surname>Poposka</surname><given-names>L</given-names></name><name><surname>Ruschitzka</surname><given-names>F</given-names></name><name><surname>Tendera</surname><given-names>M</given-names></name><name><surname>Van Gelder</surname><given-names>IC</given-names></name><name><surname>Wilson</surname><given-names>CM</given-names></name></person-group><article-title>2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA)</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><fpage>2281</fpage><lpage>2329</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/eht150</pub-id><pub-id pub-id-type="pmid">23801822</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maisel</surname><given-names>WH</given-names></name></person-group><article-title>Physician management of pacemaker and implantable cardioverter defibrillator advisories</article-title><source>Pacing Clin Electrophysiol</source><year>2004</year><volume>27</volume><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8159.2004.00460.x</pub-id><pub-id pub-id-type="pmid">15078394</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chau</surname><given-names>E</given-names></name><name><surname>Chan</surname><given-names>RH</given-names></name><name><surname>Kong</surname><given-names>SL</given-names></name><name><surname>Tang</surname><given-names>MO</given-names></name><name><surname>Christensen</surname><given-names>J</given-names></name><name><surname>Stadler</surname><given-names>RW</given-names></name><name><surname>Lau</surname><given-names>CP</given-names></name></person-group><article-title>Intrathoracic impedance monitoring in patients with heart failure correlation with fluid status and feasibility of early warning preceding hospitalization</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>841</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.492207</pub-id><pub-id pub-id-type="pmid">16061743</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prochazka</surname><given-names>A</given-names></name><name><surname>Korpas</surname><given-names>D</given-names></name></person-group><article-title>Monitoring biventricular pacing parameters dependingon the left ventricle lead configuration</article-title><source>Exp Clin Cardiol</source><year>2013</year><volume>18</volume><issue>2</issue><fpage>85</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">23940426</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>January</surname><given-names>CT</given-names></name><name><surname>Wann</surname><given-names>LS</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Calkins</surname><given-names>H</given-names></name><name><surname>Cigarroa</surname><given-names>JE</given-names></name><name><surname>Cleveland</surname><given-names>JC</given-names><suffix>Jr</suffix></name><name><surname>Conti</surname><given-names>JB</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><name><surname>Ezekowitz</surname><given-names>MD</given-names></name><name><surname>Field</surname><given-names>ME</given-names></name><name><surname>Murray</surname><given-names>KT</given-names></name><name><surname>Sacco</surname><given-names>RL</given-names></name><name><surname>Stevenson</surname><given-names>WG</given-names></name><name><surname>Tchou</surname><given-names>PJ</given-names></name><name><surname>Tracy</surname><given-names>CM</given-names></name><name><surname>Yancy</surname><given-names>CW</given-names></name><collab>American College of Cardiology/American Heart Association Task Force on Practice Guidelines</collab></person-group><article-title>2014 ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>64</volume><issue>21</issue><fpage>e1-76</fpage><pub-id pub-id-type="doi">10.1016/j.jacc.2014.03.021</pub-id><pub-id pub-id-type="pmid">24685669</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priori</surname><given-names>SG</given-names></name><name><surname>Blomstr&#x000f6;m-Lundqvist</surname><given-names>C</given-names></name><name><surname>Mazzanti</surname><given-names>A</given-names></name><name><surname>Blom</surname><given-names>N</given-names></name><name><surname>Borggrefe</surname><given-names>M</given-names></name><name><surname>Camm</surname><given-names>J</given-names></name><name><surname>Elliott</surname><given-names>PM</given-names></name><name><surname>Fitzsimons</surname><given-names>D</given-names></name><name><surname>Hatala</surname><given-names>R</given-names></name><name><surname>Hindricks</surname><given-names>G</given-names></name><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Kjeldsen</surname><given-names>K</given-names></name><name><surname>Kuck</surname><given-names>KH</given-names></name><name><surname>Hernandez-Madrid</surname><given-names>A</given-names></name><name><surname>Nikolaou</surname><given-names>N</given-names></name><name><surname>Norekv&#x000e5;l</surname><given-names>TM</given-names></name><name><surname>Spaulding</surname><given-names>C</given-names></name><name><surname>Van Veldhuisen</surname><given-names>DJ</given-names></name></person-group><article-title>2015&#x000a0;ESC&#x000a0;Guidelines&#x000a0;for the&#x000a0;management&#x000a0;of&#x000a0;patients&#x000a0;with&#x000a0;ventricular&#x000a0;arrhythmias&#x000a0;and the&#x000a0;prevention&#x000a0;of&#x000a0;sudden cardiac death: The Task Force for the&#x000a0;Management&#x000a0;of&#x000a0;Patients&#x000a0;with&#x000a0;Ventricular&#x000a0;Arrhythmias&#x000a0;and the&#x000a0;Prevention&#x000a0;of&#x000a0;Sudden Cardiac Death&#x000a0;of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)</article-title><source>Eur Heart J</source><year>2015</year><volume>36</volume><issue>41</issue><fpage>2793</fpage><lpage>2867</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv316</pub-id><pub-id pub-id-type="pmid">26320108</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forleo</surname><given-names>GB</given-names></name><name><surname>Della Rocca</surname><given-names>DG</given-names></name><name><surname>Papavasileiou</surname><given-names>LP</given-names></name><name><surname>Molfetta</surname><given-names>AD</given-names></name><name><surname>Santini</surname><given-names>L</given-names></name><name><surname>Romeo</surname><given-names>F</given-names></name></person-group><article-title>Left ventricular pacing with a new quadripolartransvenous lead for CRT: earlyresults of a prospective comparison with conventional implant outcomes</article-title><source>Heart Rhythm</source><year>2011</year><volume>8</volume><fpage>31</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2010.09.076</pub-id><pub-id pub-id-type="pmid">20887804</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Packer</surname><given-names>M</given-names></name></person-group><article-title>Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure</article-title><source>J Card Fail</source><year>2001</year><volume>7</volume><fpage>176</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1054/jcaf.2001.25652</pub-id><pub-id pub-id-type="pmid">11420770</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiner</surname><given-names>H</given-names></name><name><surname>Geist</surname><given-names>M</given-names></name><name><surname>Goldenberg</surname><given-names>I</given-names></name><name><surname>Suleiman</surname><given-names>M</given-names></name><name><surname>Glikson</surname><given-names>M</given-names></name><name><surname>Tenenbaum</surname><given-names>A</given-names></name><name><surname>Swissa</surname><given-names>M</given-names></name><name><surname>Fisman</surname><given-names>EZ</given-names></name><name><surname>Golovchiner</surname><given-names>G</given-names></name><name><surname>Strasberg</surname><given-names>B</given-names></name><name><surname>Barsheshet</surname><given-names>A</given-names></name><collab>Israeli Working Group of Pacing and EP</collab></person-group><article-title>Characteristics and outcomes of diabetic patients with an implantable cardioverter defibrillator in a real world setting: results from the Israeli ICD registry</article-title><source>Cardiovasc Diabetol</source><year>2016</year><volume>15</volume><issue>1</issue><fpage>160</fpage><pub-id pub-id-type="doi">10.1186/s12933-016-0478-2</pub-id><pub-id pub-id-type="pmid">27905927</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biffi</surname><given-names>M</given-names></name><name><surname>Moschini</surname><given-names>C</given-names></name><name><surname>Bertini</surname><given-names>M</given-names></name><name><surname>Saporito</surname><given-names>D</given-names></name><name><surname>Ziacchi</surname><given-names>M</given-names></name><name><surname>Diemberger</surname><given-names>I</given-names></name><name><surname>Valzania</surname><given-names>C</given-names></name><name><surname>Domenichini</surname><given-names>G</given-names></name><name><surname>Cervi</surname><given-names>E</given-names></name><name><surname>Martignani</surname><given-names>C</given-names></name><name><surname>Sangiorgi</surname><given-names>D</given-names></name><name><surname>Branzi</surname><given-names>A</given-names></name><name><surname>Boriani</surname><given-names>G</given-names></name></person-group><article-title>Phrenicstimulation a challenge for cardiac resynchronization therapy</article-title><source>Circ: Arrhythm Electrophysiol.</source><year>2009</year><volume>2</volume><issue>4</issue><fpage>402</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">19808496</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>M</given-names></name><name><surname>Schau</surname><given-names>T</given-names></name><name><surname>Moeller</surname><given-names>V</given-names></name><name><surname>Neuss</surname><given-names>M</given-names></name><name><surname>Meyhoefer</surname><given-names>J</given-names></name><name><surname>Butter</surname><given-names>C</given-names></name></person-group><article-title>Influence of pacing configurations, body mass index, and position of coronary sinus lead on frequency of phrenic nerve stimulation and pacing thresholds under cardiac resynchronization therapy</article-title><source>Europace</source><year>2010</year><volume>12</volume><issue>7</issue><fpage>961</fpage><lpage>967</lpage><pub-id pub-id-type="doi">10.1093/europace/euq119</pub-id><pub-id pub-id-type="pmid">20444725</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallier</surname><given-names>MS</given-names></name><name><surname>Rinaldi</surname><given-names>CA</given-names></name></person-group><article-title>First prospective, multi-centre clinical experience with a novel left ventricular quadripolarlead</article-title><source>Europace</source><year>2012</year><volume>14</volume><fpage>365</fpage><pub-id pub-id-type="doi">10.1093/europace/eur322</pub-id><pub-id pub-id-type="pmid">21993431</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Champagne</surname><given-names>J</given-names></name><name><surname>Healey</surname><given-names>JS</given-names></name><name><surname>Krahn</surname><given-names>AD</given-names></name><name><surname>Philippon</surname><given-names>F</given-names></name><name><surname>Gurevitz</surname><given-names>O</given-names></name><name><surname>Swearingen</surname><given-names>A</given-names></name><name><surname>Glikson</surname><given-names>M</given-names></name></person-group><article-title>The effect of electronic repositioning on left ventricular pacing and phrenic nerve stimulation</article-title><source>Europace</source><year>2011</year><volume>13</volume><issue>3</issue><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1093/europace/euq499</pub-id><pub-id pub-id-type="pmid">21273196</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behar</surname><given-names>JM</given-names></name><name><surname>Bostock</surname><given-names>J</given-names></name><name><surname>Zhu Li</surname><given-names>AP</given-names></name><name><surname>Chin</surname><given-names>HM</given-names></name><name><surname>Jubb</surname><given-names>S</given-names></name><name><surname>Lent</surname><given-names>E</given-names></name><name><surname>Gamble</surname><given-names>J</given-names></name><name><surname>Foley</surname><given-names>PW</given-names></name><name><surname>Betts</surname><given-names>TR</given-names></name><name><surname>Rinaldi</surname><given-names>CA</given-names></name><name><surname>Herring</surname><given-names>N</given-names></name></person-group><article-title>Cardiac resynchronization therapy delivered via a multipolar left ventricular lead is associated with reduced mortality and elimination of phrenic nerve stimulation: long-term follow-up from a multicenter registry</article-title><source>J Cardiovasc Electrophysiol</source><year>2015</year><volume>26</volume><issue>5</issue><fpage>540</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1111/jce.12625</pub-id><pub-id pub-id-type="pmid">25631303</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>MA</given-names></name><name><surname>Khiani</surname><given-names>R</given-names></name><name><surname>Foley</surname><given-names>P</given-names></name><name><surname>Webster</surname><given-names>D</given-names></name><name><surname>Qureshi</surname><given-names>N</given-names></name><name><surname>Wong</surname><given-names>KC</given-names></name><name><surname>Rajappan</surname><given-names>K</given-names></name><name><surname>Bashir</surname><given-names>Y</given-names></name><name><surname>Betts</surname><given-names>TR</given-names></name></person-group><article-title>Inter- and intravein differences in cardiac output with cardiac resynchronization pacing using a multipolar LV pacing lead</article-title><source>Pacing Clin Electrophysiol</source><year>2015</year><volume>38</volume><issue>2</issue><fpage>267</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1111/pace.12531</pub-id><pub-id pub-id-type="pmid">25414088</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoppe</surname><given-names>UC</given-names></name><name><surname>Casares</surname><given-names>JM</given-names></name><name><surname>Eiskjaer</surname><given-names>H</given-names></name><name><surname>Hagemann</surname><given-names>A</given-names></name><name><surname>Cleland</surname><given-names>JG</given-names></name><name><surname>Free-mantle</surname><given-names>N</given-names></name><name><surname>Erdmann</surname><given-names>E</given-names></name></person-group><article-title>Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.614560</pub-id><pub-id pub-id-type="pmid">16801461</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lellouche</surname><given-names>N</given-names></name><name><surname>De Diego</surname><given-names>C</given-names></name><name><surname>Vaseghi</surname><given-names>M</given-names></name><name><surname>Buch</surname><given-names>E</given-names></name><name><surname>Cesario</surname><given-names>DA</given-names></name><name><surname>Mahajan</surname><given-names>A</given-names></name><name><surname>Wiener</surname><given-names>I</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name><name><surname>Boyle</surname><given-names>NG</given-names></name><name><surname>Shivkumar</surname><given-names>K</given-names></name></person-group><article-title>Cardiac resynchronization therapy response is associated with shorter duration of atrial fibrillation</article-title><source>Pacing Clin Electrophysiol</source><year>2007</year><volume>30</volume><issue>11</issue><fpage>1363</fpage><lpage>1368</lpage><pub-id pub-id-type="doi">10.1111/j.1540-8159.2007.00872.x</pub-id><pub-id pub-id-type="pmid">17976100</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>R</given-names></name><name><surname>Lau</surname><given-names>DH</given-names></name><name><surname>Sanders</surname><given-names>P</given-names></name></person-group><article-title>Impact of obesity on cardiac metabolism, fibrosis, and function</article-title><source>Trends Cardiovasc Med</source><year>2015</year><volume>25</volume><issue>2</issue><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2014.09.005</pub-id><pub-id pub-id-type="pmid">25446049</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>R</given-names></name><name><surname>Lau</surname><given-names>DH</given-names></name><name><surname>Brooks</surname><given-names>AG</given-names></name><name><surname>Shipp</surname><given-names>NJ</given-names></name><name><surname>Manavis</surname><given-names>J</given-names></name><name><surname>Wood</surname><given-names>JP</given-names></name><name><surname>Finnie</surname><given-names>JW</given-names></name><name><surname>Samuel</surname><given-names>CS</given-names></name><name><surname>Royce</surname><given-names>SG</given-names></name><name><surname>Twomey</surname><given-names>DJ</given-names></name><name><surname>Thanigaimani</surname><given-names>S</given-names></name><name><surname>Kalman</surname><given-names>JM</given-names></name><name><surname>Sanders</surname><given-names>P</given-names></name></person-group><article-title>Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>66</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2015.04.058</pub-id><pub-id pub-id-type="pmid">26139051</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cal&#x000f2;</surname><given-names>L</given-names></name><name><surname>Martino</surname><given-names>DeRuvo E</given-names></name><name><surname>Minati</surname><given-names>M</given-names></name><name><surname>Fratini</surname><given-names>S</given-names></name><name><surname>Rebecchi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Acute echocardiographic optimization of multiple stimulation configurations of cardiac resynchronization therapy through quadripolar left ventricular pacing: a tailored approach</article-title><source>Am Heart J</source><year>2014</year><volume>167</volume><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2013.12.028</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szepietowska</surname><given-names>B</given-names></name><name><surname>Polonsky</surname><given-names>B</given-names></name><name><surname>Sherazi</surname><given-names>S</given-names></name><name><surname>Biton</surname><given-names>Y</given-names></name><name><surname>Kutyifa</surname><given-names>V</given-names></name><name><surname>McNitt</surname><given-names>S</given-names></name><name><surname>Aktas</surname><given-names>M</given-names></name><name><surname>Moss</surname><given-names>AJ</given-names></name><name><surname>Zareba</surname><given-names>W</given-names></name></person-group><article-title>Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events</article-title><source>Cardiovasc Diabetol</source><year>2016</year><volume>15</volume><fpage>93</fpage><pub-id pub-id-type="doi">10.1186/s12933-016-0401-x</pub-id><pub-id pub-id-type="pmid">27388610</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera</surname><given-names>BF</given-names></name><name><surname>Alzueta</surname><given-names>RJ</given-names></name><name><surname>Olaguede</surname><given-names>RJ</given-names></name><name><surname>Fernandez-Lozano</surname><given-names>I</given-names></name><name><surname>Garc&#x00131;a Guerrero</surname><given-names>JJ</given-names></name><name><surname>de la Concha</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Improvement in hemodynamic better programmability with quartet than bi- and tripolar equivalents</article-title><source>Pacing Clin Electrophysiol</source><year>2013</year><volume>36</volume><fpage>963</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1111/pace.12172</pub-id><pub-id pub-id-type="pmid">23692289</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Hua</surname><given-names>W</given-names></name><name><surname>Ding</surname><given-names>LG</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>KP</given-names></name><name><surname>Yang</surname><given-names>XW</given-names></name><name><surname>Liu</surname><given-names>ZM</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title>Association of body mass index with cardiac reverse remodeling and long-term outcome in advanced heart failure patients with cardiac resynchronization therapy</article-title><source>Circ J</source><year>2014</year><volume>78</volume><issue>12</issue><fpage>2899</fpage><lpage>2907</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-14-0812</pub-id><pub-id pub-id-type="pmid">25345991</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Axelsen</surname><given-names>LN</given-names></name><name><surname>Calloe</surname><given-names>K</given-names></name><name><surname>Braunstein</surname><given-names>TH</given-names></name><name><surname>Riemann</surname><given-names>M</given-names></name><name><surname>Hofgaard</surname><given-names>JP</given-names></name><name><surname>Liang</surname><given-names>B</given-names></name><name><surname>Jensen</surname><given-names>CF</given-names></name><name><surname>Olsen</surname><given-names>KB</given-names></name><name><surname>Bartels</surname><given-names>ED</given-names></name><name><surname>Baandrup</surname><given-names>U</given-names></name><name><surname>Jespersen</surname><given-names>T</given-names></name><name><surname>Nielsen</surname><given-names>LB</given-names></name><name><surname>Holstein-Rathlou</surname><given-names>NH</given-names></name><name><surname>Nielsen</surname><given-names>MS</given-names></name></person-group><article-title>Diet-induced pre-diabetes slows cardiac conductance and promotes arrhythmogenesis</article-title><source>Cardiovasc Diabetol</source><year>2015</year><volume>14</volume><fpage>87</fpage><pub-id pub-id-type="doi">10.1186/s12933-015-0246-8</pub-id><pub-id pub-id-type="pmid">26169175</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sardu</surname><given-names>C</given-names></name><name><surname>Santamaria</surname><given-names>M</given-names></name><name><surname>Rizzo</surname><given-names>MR</given-names></name><name><surname>Barbieri</surname><given-names>M</given-names></name><name><surname>di Marino</surname><given-names>M</given-names></name><name><surname>Paolisso</surname><given-names>G</given-names></name><name><surname>Santulli</surname><given-names>G</given-names></name><name><surname>Marfella</surname><given-names>R</given-names></name></person-group><article-title>Telemonitoring in heart failure patients treated by cardiac resynchronization therapy with defibrillator (CRT-D): the TELECART Study</article-title><source>Int J ClinPract.</source><year>2016</year><volume>70</volume><issue>7</issue><fpage>569</fpage><lpage>576</lpage></element-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Sardu C, Barbieri M, Rizzo MR, Paolisso P, Paolisso G, Marfella R. Cardiac resynchronization therapy outcomes in type 2 diabetic patients: role of MicroRNA changes. J Diabetes Res. 2016:7292564.</mixed-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sardu</surname><given-names>C</given-names></name><name><surname>Marfella</surname><given-names>R</given-names></name><name><surname>Santulli</surname><given-names>G</given-names></name><name><surname>Paolisso</surname><given-names>G</given-names></name></person-group><article-title>Functional role of miRNA in cardiac resynchronization therapy</article-title><source>Pharmacogenomics</source><year>2014</year><volume>8</volume><fpage>1159</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.2217/pgs.14.76</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umar</surname><given-names>F</given-names></name><name><surname>Taylor</surname><given-names>RJ</given-names></name><name><surname>Stegemann</surname><given-names>B</given-names></name><name><surname>Marshall</surname><given-names>H</given-names></name><name><surname>Flannigan</surname><given-names>S</given-names></name><name><surname>Lencioni</surname><given-names>M</given-names></name><name><surname>De Bono</surname><given-names>J</given-names></name><name><surname>Griffith</surname><given-names>M</given-names></name><name><surname>Leyva</surname><given-names>F</given-names></name></person-group><article-title>Haemodynamic effects of cardiac resynchronization therapy using single-vein, three-pole, multipoint left ventricular pacing in patients with ischaemic cardiomyopathy and a left ventricular free wall scar: the MAESTRO study</article-title><source>Europace</source><year>2016</year><volume>18</volume><issue>8</issue><fpage>1227</fpage><lpage>1234</lpage><pub-id pub-id-type="doi">10.1093/europace/euv396</pub-id><pub-id pub-id-type="pmid">26718535</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shetty</surname><given-names>AK</given-names></name><name><surname>Sohal</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Ginks</surname><given-names>MR</given-names></name><name><surname>Bostock</surname><given-names>J</given-names></name><name><surname>Amraoui</surname><given-names>S</given-names></name><name><surname>Ryu</surname><given-names>K</given-names></name><name><surname>Rosenberg</surname><given-names>SP</given-names></name><name><surname>Niederer</surname><given-names>SA</given-names></name><name><surname>Gill</surname><given-names>J</given-names></name><name><surname>Carr-White</surname><given-names>G</given-names></name><name><surname>Razavi</surname><given-names>R</given-names></name><name><surname>Rinaldi</surname><given-names>CA</given-names></name></person-group><article-title>A comparison of left ventricular endocardial, multisite, and multipolar epicardial cardiac resynchronization: an acute haemodynamic and electroanatomical study</article-title><source>Europace</source><year>2014</year><volume>16</volume><issue>6</issue><fpage>873</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1093/europace/eut420</pub-id><pub-id pub-id-type="pmid">24525553</pub-id></element-citation></ref></ref-list></back></article>